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Wastewater spiked with chemicals representing persistent contaminants was applied to a 
pilot-scale constructed wetland containing a locally sourced substrate on which a biofilm had 
developed. The system utilized aerobic, hypoxic, and aerobic columns, and was evaluated for its 
removal of estrogenic activity from wastewater using the yeast estrogen screen, as a function of 
five different dosing intervals.  The removal of activity, as measured by estrogen equivalents 
(EEQ), decreased as the length of the dosing interval increased, with an 8 hour dosing interval 
achieving the highest removal at 99.9%. For all dosing studies, higher removals in activity were 
achieved by employing the columns in series than was achieved by any one column individually. 
Moreover, it was found that hypoxic conditions resulted in a higher removal of EEQ, suggesting 
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CHAPTER 1: BACKGROUND 
1.1  Environmental Relevance of Endocrine Disruption 
The human endocrine system is responsible for chemical signaling and the maintenance of 
homeostasis. Chemical signaling occurs through the synthesis and transport of endogenous 
hormones that control the growth, development, and metabolism of the body. In humans, the 
endocrine system is composed of several glands including the hypothalamus, pituitary gland, 
adrenal glands, thyroid, parathyroid, pancreas, and the gonads (i.e. testes and ovaries). These 
seven glands are responsible for synthesizing and secreting endogenous hormones into the blood 
stream where they disperse, bind to hormone specific receptors, and initiate tissue and cell-
specific biological effects.  
Certain exogenous chemicals are capable of mimicking endogenous hormones, causing 
alterations in normal endocrine signaling and potential adverse biological effects, a process 
known as endocrine disruption. According to the Society of Toxicology, the generally accepted 
definition for endocrine disruption is “an exogenous substance that causes adverse health effects 
in an intact organism, or its progeny, secondary to changes in the endocrine function” (Society of 
Toxicology, 2010). Endocrine disruption has been shown to cause deleterious effects in wildlife. 
Notable extreme examples include the rapid decline of high level bird species due to 
dichlorodiphenyltrichloroethane (DDT) exposure detailed in Rachel Carson’s Silent Spring, and 
feminization of male fish in heavily polluted waters (Carson, Lois, Darling, Wilson, & Lear, 
2003; Kabir, Rahman, & Rahman, 2015). Endocrine disruption remains relevant in the human 





has been linked to various cancer and reproductive health endpoints (Diamanti-Kandarakis et. 
al., 2009).  A prospective human cohort study has demonstrated a link between in utero exposure 
to DDT and increased risk of breast cancer (Cohn et. al., 2015). The estrogen disruptor 
diethylstilbestrol (DES), which was prescribed to pregnant mothers to prevent miscarriage, is an 
even starker example of the potential health effects of estrogen disruption. It is estimated that 
between five and ten million mothers were prescribed DES before it was removed from markets 
due to increased incidence of clear-cell carcinoma, anatomical malformations of the reproductive 
tract, and decreased fertility in daughters exposed in utero (Cohn et. al., 2015; Henley & Korach, 
2006; Soto & Sonnenschein, 2015).  
While many of the aforementioned examples represent the effects of high and direct doses of 
chemicals, there is rising concern about chronic low level human exposure to endocrine 
disrupting compounds (EDCs) because their presence at low levels in the environment has been 
shown to demonstrate adverse developmental, reproductive, neural and immune health effects in 
mammals (Yang, Kim, Weon, & Seo, 2015). In fact, most research has focused on the negative 
effects of EDCs on sexual development and reproduction caused by interference with the 
estrogen receptor (ER) because the outcome is readily identifiable and represents a sensitive 
health issue for the general public (Henley & Korach, 2006). Inappropriate ER signaling can lead 
to increased risk of hormone-dependent cancer, impaired fertility, as well as abnormal fetal 
growth and development (Diamanti-Kandarakis et. al., 2009). Moreover, current epidemiological 
evidence also points to an association between increased environmental exposure to exogenous 
EDCs and increased incidence of such biological endpoints (Vandenberg et. al., 2012).  
Emerging contaminants are defined by the United States Environmental Protection Agency 





human health or the health of the environment or by a lack of published health standards” (US 
EPA, 2016). Many of these contaminants are suspected estrogen disruptors and are of particular 
concern because the consequences of their presence in surface waters remain largely unknown. 
Moreover, they are present in the environment in complex mixtures and while many individual 
compounds have been studied in depth for their estrogen disrupting capabilities, there is not yet 
enough information regarding mixtures of such compounds. In order to better protect human and 
environmental health from the impact of EDCs, evaluation of chemical mixtures in 
environmental samples using effective screening tools is required.   
 
1.2  Mechanisms of Estrogen Signaling 
The biochemical messages of the estrogen system are mediated through activation and 
repression of the estrogen receptor, a member of the steroid nuclear receptor family.  Steroid 
nuclear receptors are also referred to as transcription factors due to their role in regulating target 
gene transcription (Smirnova, 2015).  They are globular oligomeric proteins that exhibit complex 
three dimensional conformations which are critical to their biological function. For the estrogen 
receptor there are two subtypes, the ERα and the ERβ, which are very similar but have key 
structural differences that explain their different ligand affinities and target genes (Shanle & Xu, 
2011).  Estrogen receptors can mediate biochemical changes in target cells and tissues through 
genomic and nongenomic estrogen signaling.  The genomic pathway consists of ligand-
dependent modulation of gene expression through activation of the receptor. The nongenomic 
pathway is less readily understood but is thought to occur via ligand binding to membrane bound 
receptors, which can be either of the ERα or ERβ subtypes or another receptor type entirely, such 
as a G-protein coupled receptor. This pathway causes cellular signaling cascades that lead to 





 There are four main components of each receptor: the N-terminus (free amino terminus) 
containing the activator function 1 (AF1), the central DNA binding domain (DBD), a hinge 
region, and the ligand binding domain (LBD) containing the free carboxy terminus of the 
polypeptide and a second activator function (AF2) (Smirnova, 2015). The N-terminus is the most 
variable segment of the protein and its major role is housing the AF1, which is responsible for 
recruiting important cofactors and coregulators, in addition to playing a crucial role in tethering 
DNA to the receptor. The AF1 and AF2 regions are used to up- or down-regulate subsequent 
DNA binding, depending on cell type and the availability of coregulators near the ligand-
receptor complex (Shanle & Xu, 2011). The most highly conserved region of the receptor is the 
DBD as it is required for proper recognition and binding of estrogen response elements (EREs) – 
a series of unique palindromic base pair repeats that are found upstream of target genes and help 
signal the transcription start site. The LBD is the region in which compatible ligands (i.e. an 
endogenous hormone or an exogenous EDC) bind to the receptor, acting as the initiating step of 
ligand-dependent receptor signaling. Finally, the hinge region connects the highly conserved 
LBD and DBD, acting as a spacer region and an interface for dimerization of the receptor 
complex (Heldring et. al., 2007).  
 In three dimensions, the LBD of the ER, also known as the receptor’s active site, exists as a 
wide pocket in the surface of the protein. The arrangement of the independently folding alpha 
helices of the receptor protein creates a “wedged-shaped” molecular scaffold that maintains a 
large cavity in the protein’s LBD in which a substrate can bind (Brzozowski et. al., 1997; Shanle 
& Xu, 2011). Binding of the LBD to a compatible ligand causes a shift in the conformation of 
the receptor structure that can either promote (agonism) or prevent (antagonism) subsequent 





receptor, the bound receptor must dimerize with a second receptor before it can translocate to the 
nucleus and bind EREs upstream of target genes. The presence of two ER subtypes means that 
the ER can form a heterodimer (an ERα and ERβ complex) or a homodimer (a complex of two 
identical ERs), depending on the intracellular availability of the two receptor subtypes. Agonists 
and antagonists bind at the same site in the LBD but induce distinct conformations in the 
transactivational domain of the LBD that either allows for continued signal transduction 
(agonism) or halting of the signaling pathway (antagonism) (Brzozowski et. al., 1997).   
There are several important characteristics of a potential ligand that determine whether it will 
act as an agonist or an antagonist. In the case of the ERα, X-ray crystallography of a receptor 
bound with the endogenous hormone 17-β-estradiol (E2) shows there are three critical hydrogen 
bonding interactions between E2 and the amino acids Glu353, Arg394, and His524 (or Glu305, 
Arg346, and His475 in the ERβ) (Shanle & Xu, 2011). The series of hydrogen bonding, in 
conjunction with strong hydrophobic interactions between the aromatic rings of E2 and nonpolar 
amino acids in the binding pocket, stabilizes the ligand-receptor complex, allowing for a 
conformational shift in alpha helix 12. Helix 12 flips over, forming a cap on the binding pocket 
and activating the AF2, which is critical to downstream DNA binding and gene transcription 
(Brzozowski et. al., 1997; Smirnova, 2015). When bound to an ER antagonist, helix 12 protrudes 
from its neighboring helices in a conformation that prevents dimerization and halts the signaling 
pathway.  
When discussing receptor mediated gene transcription in the context of endocrine disruption, 
it is important to note that the ERs have a sizeable binding cavity within the face of the protein 
(Brzozowski et.al., 1997). As a result, even though the system of hydrogen bonds and 





endogenous hormone to receptor, other molecules that possess similar nonpolar and hydrogen 
bonding moieties can exhibit binding as well.  Such compounds are capable of binding to the 
receptor, although often at a much lower binding affinity than endogenous hormones, influencing 
gene transcription.  
 
1.3 Bioassays Used to Evaluate Estrogen Disruptors 
 Chemical methods for analyzing environmental samples containing mixtures of emerging 
contaminants are inadequate for assessing their endocrine activity (Kinnberg, 2003; Leusch, 
2008; Osman, AbouelFadl, Krüger, & Kloas, 2015). For many emerging contaminants, their 
potential to act as an EDC is unknown; individual chemicals may cause biological effects at 
concentrations below analytical detection limit, and in mixtures that effect may be different than 
its effect individually (Leusch, 2008). In mixtures, synergism can occur where the overall effect 
is larger than the sum of the effects of the individual components, or antagonism can occur, 
where the overall effect is smaller than predicted from the sum of the effects of each component. 
Thus, attempts to determine the endocrine activity of environmental samples using chemical 
analysis can lead to an underestimation or overestimation of the true activity. As a result, there 
has been a movement towards using in vitro bioassays as screening tools for measuring activity 
in environmental samples due to their ability to capture total estrogenic activity without requiring 
prior knowledge of the specific chemical composition of the sample (Jia et. al., 2015; Kinnberg, 
2003; Krein et. al., 2012; Leusch, 2008; Soto, Maffini, Schaeberle, & Sonnenschein, 2006). 
Moreover, it has been demonstrated that integration of information from chemical analysis and 
bioassays can provide a more complete understanding of estrogenic activity of environmental 
waters. In this manner, bioassays can be used to screen for estrogenic exposures, identify point 





Schaeberle, & Sonnenschein, 2006). There are three major classes of bioassays that are 
commonly used to evaluate potential estrogen disruptors: competitive binding receptor, cell 
proliferation, and reporter gene assays. 
 Competitive receptor binding assays are a common non-cell based assay used to assess the 
ability of a compound or sample to bind to the receptor’s LBD (Soto, Maffini, Schaeberle, & 
Sonnenschein, 2006). These assays test the first event in the complex signal transduction 
pathway of ligand-dependent receptor-mediated endocrine function from which all downstream 
signaling initiates (or terminates) (Murk et. al., 2002). These assays utilize purified ER protein 
that are co-exposed to a native ligand (E2) and sample of interest and its ability to inhibit the 
binding of E2 is monitored. These assays quantify the ability of a sample to compete for the 
receptor’s active site, but do not give information about biological mechanism of action (i.e. 
agonism or antagonism) (Murk et. al., 2002). While these assays are required for absolute 
confirmation of a compound as an estrogen disruptor, they are time consuming and require 
highly trained workers and specialized equipment, making them poor choices for environmental 
screening tools (Kinnberg, 2003). In addition, these non-cell based assays do not account for 
cellular uptake of a given compound and, thus, may overestimate risk for compounds whose 
physical and chemical properties prevent them from crossing cell membranes.  
The next set of bioassays commonly used are cell proliferation assays, which test the ability 
of a compound to increase proliferation of human breast cancer (MCF-7) cells. Cells are cultured 
in media containing proliferation inhibiting factors, and the ability of a compound to overcome 
these inhibitory factors and induce proliferation is measured. While these assays are sensitive, 
they have been shown to be less estrogen specific, as there are many other processes independent 





The final group are reporter gene assays, which can be conducted using either mammalian or 
yeast cells stably transfected with a reporter plasmid (and in the case of yeast cells, stably 
transfected with the plasmid and the gene for human ER). EREs are places upstream of the 
transcriptional start site of the reporter gene, ensuring that the transcription of the gene is 
dependent on binding of an agonistic compound to the ER, subsequent dimerization, and binding 
of the dimer to the ERE.  Thus, it is possible to model the dose dependent transcription of the 
reporter gene across a dose dilution curve of sample concentration. Reporter gene assays are 
popular for environmental analysis because of their higher throughput, greater sensitivity and 
specificity of mode of action (i.e. genomic ER signaling) (Jia et al., 2015).  Cell based reporter 
gene assays have been shown to better correlate with in vivo study results than ER binding and 
cell proliferation assays, likely due to their ability to account for toxicokinetics at the cellular 
level and their higher mode of action specificity (Kinnberg, 2003). The sensitivity of reporter 
gene assays depends on the cell type employed, with yeast based assays having lower sensitivity 
than those employing mammalian cells. However, yeast cells have shown to perform well on 
highly polluted water and, thus, can be applied to wastewater matrices with a lower risk of 
cytotoxicity (Leusch et. al., 2010). While mammalian reporter gene assays are more sensitive 
with lower detection limits than yeast based assays, mammalian cells are much more difficult to 
culture and are less resilient when exposed to highly polluted samples (Kinnberg, 2003; Leusch 
et al., 2010). Although yeast cells contain a cell wall that might prevent cellular uptake and, thus, 
underestimate estrogenic activity, they are a low cost, higher throughput option (Soto, Maffini, 
Schaeberle, & Sonnenschein, 2006).  As a result, yeast based reporter gene assays are a very 
useful screening tool that can be used to evaluate wastewater.  





estrogen activity. In vitro assays involve single cells and do not accurately represent some 
important toxicological processes that determine how a compound will affect an entire organism, 
namely the concepts of absorption, distribution, metabolism and elimination. At the organismal 
level, compounds may be endocrine active but may be metabolized into a compound that is not 
active prior to exhibiting biological effects of disruption, making it of less physiological 
relevance. In addition, an organism may be exposed to a compound but it may not be 
bioavailable to the cells in which it has an effect. As a result, cellular response will not always 
imply higher-level effects, but they are a prerequisite for effects at the organismal or population 
level (Escher et. al., 2014). Moreover, from a precautionary public health standpoint the potential 
to cause adverse effects is still a “critical assessment endpoint” (Escher et. al., 2014). So while 
cell-based reporter gene assays cannot replace in vivo testing, they can provide hazard 
information for screening and prioritization (Judson et. al., 2013). 
 
1.4 Environmental Exposures of EDCs 
 Estrogen mimics are thought to enter the aquatic environment largely through municipal 
and industrial sewage discharge into surface waters (Kinnberg, 2003; Schenck et. al., 2012). 
Urban and agricultural run-off also contribute to elevated levels of EDCs in waterways (Kabir, 
Rahman, & Rahman, 2015). Major potent estrogen species include natural and synthetic steroid 
hormones (used as birth control and treatment for menopausal disorders) such as estrone, E2, and 
17-a-ethinylestradiol (EE). Common low-potency estrogen disruptors include the surfactant 
degradate nonylphenol (released from homes and the dry cleaning industry), flame retardants, 
polychlorinated biphenols (industrial production), phthalates (found in personal care products), 
natural phytoestrogens, pharmaceuticals, and pesticides (Céspedes et. al., 2004; Kabir, Rahman, 





mixtures of these low-potency disruptors which are present in the low µg/L range (Crain et. al., 
2007; Gunnarsson et. al., 2009; Luo et. al., 2014).  
In the field of toxicology there is a central theme of “the dose makes the poison,” which 
essentially means that exposure to low doses of chemicals is less of a concern than high doses 
simply due to their concentration. However, this same concept cannot be readily applied to the 
area of endocrine disruption because EDCs can have effects at low doses, often below chemical 
detection limits, that are not predicted by their effects at high doses (Vandenberg et. al., 2012). 
Given that circulations of endogenous hormones are so low, even low doses of endocrine active 
compounds can cause dramatic changes in hormonal homeostasis and have widespread effects 
that are different or even opposite of the effects of the hormone at high doses.  Furthermore, 
there is a nonlinear relationship between ligand concentration and the number of bound receptors 
such that in the low dose range a 10-fold increase in hormone (or EDC) can cause a 9-fold 
increase in receptor occupancy, whereas the same increase at high doses is associated with only a 
10% increase. As a result, moderate changes in ligand concentration in the low-dose range can 
produce substantial changes in receptor occupancy and generate significant biological effects 
(Vandenberg et. al., 2012).  There has also been strong, reliable, and reproducible evidence from 
several studies that confirm the presence of low concentrations of EDCs and other chemicals in 
human tissue and fluids, as well as in environmental samples (Crain et. al., 2007).  In addition, 
there are numerous epidemiologic analyses that repeatedly find associations between the 
observed concentrations in human samples and disease endpoints. As a result, even low levels of 







1.5 Wastewater Treatment and Estrogenic Activity Removal  
The occurrence of micropollutants, many of which are estrogenic, in wastewater 
treatment plant (WWTP) influent falls in the 0.1 to 10µg/L range, but some widely used 
chemicals such as ibuprofen, atenolol, caffeine, and nonylphenol have mean occurrence values 
much higher (Luo et. al., 2014).  Removal efficiencies after conventional treatment, which 
typically includes primary or physical treatment (sedimentation) followed by secondary 
(biological) treatment to reduce the water’s biochemical oxygen demand, depend on the 
physicochemical properties of the compound and typically range from 12.5-100% (Deblonde, 
Cossu-Leguille, & Hartemann, 2011). After treatment, the concentration of many 
micropollutants are in the range of 1ng/L to 1µg/L, but many compounds persist, including 
nonylphenol, triclosan,  caffeine, and atenolol, at concentrations above 1µg/L.  
The occurrence and removal of estrogenic activity during wastewater treatment tracks 
with the removal and persistence of micropollutants.  Total estrogenic activity (expressed as 
estrogen equivalents (EEQ see section 1.7) of WWTP influents have been reported to range from 
0.6-154ng/L. Conventional wastewater treatment plants utilizing activated sludge as their 
biological treatment can reduce estrogenic activity considerably (typical effluent EEQ fall below 
25ng/L), but EEQ of up to 150ng/L in effluents have been reported in the U.S. (Kinnberg, 2003; 
Liu, Kanjo, & Mizutani, 2009). As a result, physiologically relevant levels of estrogenic activity 
persist even after conventional treatment (Pawlowski et. al., 2004; Schenck et.al., 2012; 
Westerhoff, Yoon, Snyder, & Wert, 2005). These effluents then contribute to surface water 
contamination and pose a threat to wildlife, which is susceptible to potent endocrine disruptors 





contamination of surface waters by WWTP effluent with estrogenic activity results in chronic, 
low dose exposures to fish and wildlife, the consequences of which are largely unknown.  
Given the incomplete removal of many micropollutants during conventional wastewater 
treatment, tertiary treatment is often included in municipal WWTPs. A review of 14 WWTPs 
showed that tertiary treatment processes using activated carbon, advanced oxidation processes, 
and nanofiltration achieve higher and more consistent removal than conventional WWTPs (Luo 
et. al., 2014). Several studies have shown that optimized biological treatment or other more 
advanced technologies can also increase the efficiency of the removal of estrogens (Liu, Kanjo, 
& Mizutani, 2009; Völker et. al., 2016). Other studies have shown that advanced treatment with 
ozone was capable of removing the estrogenic effects on fish exposed to WWTP effluent as 
monitored via hepatic estrogen responsive genes (Gunnarsson et. al., 2009).  Unfortunately, 
advanced treatment has a high cost and is typically only employed when higher quality water 
discharge is necessary (e.g. for water reuse) (Ávila et. al., 2014; Luo et. al., 2014). Advanced 
treatment with chemicals such as ozone and chlorine introduces concerns about the potential 
hazardous substances that are produced as byproducts (Gunnarsson et. al., 2009; Koh et. al., 
2008). As a result, exploring low cost tertiary treatment processes capable of increasing removal 
of estrogenic compounds without the use of additional chemicals becomes of increasing interest.  
One such option that has emerged as a low cost, low maintenance tertiary treatment to 
remove persistent micropollutants and, therefore, reduce estrogenic activity prior to discharge 
into the environment is the constructed wetland (CW) (Ávila et. al., 2014). This term refers to 
nonconventional water treatment systems (typically onsite at the source of wastewater 
production and storage) that use natural processes (sorption, biodegradation by microbes, 





2004). Subsurface vertical flow (VF) wetlands undergo intermittent dosing of wastewater, which 
then percolates through the sand/gravel bed. Vertical flows are often employed in series to 
alternate periods of dose and rest, which allows for greater mineralization of deposited solids 
during resting phases. Due to the intermittent dosing, VFs allow for the development of pockets 
of aerobic and anaerobic conditions. Horizontal flows (HF) are continuously fed and, therefore, 
saturated as the water flows horizontally through a vegetated gravel bed. As a result, horizontal 
flows are predominantly anaerobic in nature. Combining vertical and horizontal flow wetland 
design improves overall treatment efficiency as it allows for periods of both anaerobic and 
aerobic degradation, facilitating additional contaminant removal than CWs employing only VF 
or HF (Vymazal, 2011). CWs are effective in treating polluted waters from a wide range of 
domestic, industrial, and agricultural operations (Matamoros, Caselles-Osorio, Garcia, & 
Bayona, 2008; Vymazal, 2011). Wetland treatment had removal efficiencies ranging from 67% 
to 100% in a study looking at the removal of pharmaceuticals and alkylphenol ethoxylate 
metabolites, some of which may be possible EDCs (Gross, Montgomery-Brown, Naumann, & 
Reinhard, 2004). Moreover, it has been shown that constructed wetlands are capable of removing 
many types of pharmaceutical and personal care products, though the processes are typically not 
optimized for this objective and little is known about their potential for removing estrogenic 
activity (Conkle, White, & Metcalfe, 2008; Vymazal, 2011).  
A vertical flow constructed wetland (VFCW) can be piloted in the laboratory using large 
stainless steel columns, packed with porous rock material (typically chosen based on locally 
sourced materials). In order to pilot a VFCW undergoing intermitted dosing – where there is a 
set time interval between applications (i.e. dosing) of a volume of wastewater – several columns 





aerobic and anaerobic conditions in a full scale VF wetland. In order to simulate real world 
conditions, a wastewater matrix that has undergone some level of treatment is typically used. As 
a result, this water is cleaner than a typical wastewater influent and it becomes necessary to spike 
in target compounds in order to elevate their levels so that chemical analysis can track their fate. 
For the pilot-scale CW used in this particular study, seven target emerging contaminants have 
been chosen: atrazine (an herbicide), 4-nonylphenol (a surfactant degradant), triclosan (an 
antibiotic), carbamazepine (an antiepileptic drug), caffeine (a stimulant), E2 (a steroid hormone), 
and N,N-Diethyl-m-toluamide (DEET) (a pesticide). These are chemicals that are commonly 
found in domestic wastewater, and as mentioned previously, undergo different rates of removal 
during treatment due to their different physical-chemical properties. As a result, they represent 
large classes of contaminants and can be used as surrogates for their removal. Moreover, many 
of these compounds have biochemical activity, including estrogenic activity, making their 
removal of particular interest if the treated water is to have a wider reuse potential.  
 
1.6 Use of the Yeast Estrogen Screen to Monitor Wastewater Remediation 
As mentioned previously, the use of reporter gene assays is becoming increasingly more 
common to evaluate environmental samples for estrogenic activity.   Recombinant yeast assays, 
specifically the yeast estrogen screen (YES), take advantage of the role ERs play as transcription 
factors to assess the estrogenic capabilities of samples. In the YES assay, Saccharomyces 
cerevisiae yeast cells have been stably transfected with the gene for the human ERa in addition 
to the receptor promoted lac-Z plasmid. An ERE is placed upstream of the lac Z gene, which 
ensures that the expression of the reporter protein, β-galactosidase, is controlled by the activation 
of the corresponding ERa via binding of an agonistic ligand. The reporter protein is secreted into 





galactopyranoside (CPRG). As depicted in Figure 1, β-galactosidase catalyzes the hydrolysis of 
the galactosidic bond in CRPG (yellow), releasing chlorophenol-red, which causes the growth 
media to turn red depending on the degree of β-galactosidase production.  
 
Figure 1. Cleavage of the galactosidic bond in CPRG with the enzyme B-galactosidase 
 
Spectrophotometric detection of chlorophenol-red thus serves as a proxy for gene 
expression and receptor activation (Routledge & Sumpter, 1996). The assay is conducted in a 96-
deep well plate, which allows for an eleven-point concentration dilution series to which the yeast 
is exposed. A plot of the absorbance against the analyte concentration in each well represents the 
dose-dependent production of reporter gene for a given sample, as shown in Figure 2 for E2.  An 
effective dose 50% (EC50), which represents the concentration at which the dose response curve 
reaches 50% maximum response, is calculated for each curve. The EC50 value acts a surrogate 
for the potency of a receptor agonist and is an important measure that can be used to compare 
























































The YES assay is particularly applicable to the assessment of endocrine activity in 
environmental samples and has received attention as a rapid and relatively simple screening tool 
in laboratory and field experiments (Pawlowski et. al., 2004; Routledge & Sumpter, 1996). In 
addition, the assay is viewed as a useful screening tool to prioritize future in vivo studies and 
targeted chemical analysis for indicating potential ecological risk from hormone activities (Krein 
et. al., 2012). Of particular note is the ability to use the YES assay in testing environmental 
samples for their potential as estrogenic agonists and antagonists (Saunders, Higley, Hecker, 
Mankidy, & Giesy, 2013; Völker et. al., 2016).  
The most common method of preparing aqueous environmental samples for bioassay 
analysis is solid phase extraction (SPE).  Environmental samples typically contain mixtures of 
natural and synthetic hormones and low-potency disruptors at low concentrations and, therefore, 
it is necessary to concentrate them for subsequent instrumental and bioassay analysis (Cespedes 
et. al., 2004, Leusch et. al., 2006). Several studies have used the YES assay to test the endocrine 
activity of solid phase extracts of Rhine and Nile River samples, as well as wastewater treatment 
discharge (Osman, AbouelFadl, Krüger, & Kloas, 2015; Pawlowski et. al., 2004). Pawlowski et. 
al., (2004), determined that estrogenic activity calculated from chemical analysis resulted in 
much lower values of activity than were produced using the YES assay in Rhine River SPE 
extracts.  
 
1.7 Integrating Chemical and YES Analysis to Evaluate Mixtures of EDCs 
As mentioned previously, a major benefit of using the YES assay is the ability to capture 
total estrogenic activity of environmental samples without requiring knowledge of the individual 
chemical mixture components. This can be done using the concept of biological equivalents 





endogenous hormone that is known to activate a given biological pathway. For hormone-
dependent estrogen receptor-mediated signaling, the endogenous hormone is E2 and, thus, 
individual chemical and mixture activity can be reported as estrogen equivalents (Jia et.al., 2015, 
Leusch et. al., 2006; Leusch et. al., 2010). Using this concept, it is possible to evaluate the 
activity of individual chemicals by calculating a potency factor that relates the activity of the 
EDC to the activity of E2, which can then be multiplied by the concentration of the EDC to 
represent how much estrogen would need to be present to produce the same biological effect.  
For environmental samples, this concept is particularly useful when the identity of the sample 
components is unknown. An EEQ can be calculated for the sample by comparing the volume of 
solid phase extract that produces a given response to the amount of E2 that would be needed to 
produce that same response (Leusch et. al., 2010). This concept is essentially answering the 
question “if all the observed estrogen activity of a mixture were caused by E2, how much E2 
would be present in that mixture?”  
EEQ can also be used in conjunction with chemical analysis if the potency of the 
individual chemical analytes has been quantified. To do so requires the assumption that the 
chemicals exhibit additivity. Assuming additivity, a predicted EEQ can be determined by first 
calculating the EEQ of each individual chemical in the mixture as described above, and summing 
those values to represent the predicted activity of those components in a mixture. It is possible to 
then compare predicted EEQ values with bioassay derived EEQ values to understand what 
percentage of the detected activity can be explained by the primary estrogenic analytes in the 
sample. In addition, comparing predicted and bioassay-derived EEQs may allow for greater 






1.8 Research Objectives 
The aim of this project was to accomplish the following objectives 
1.   Use the YES assay to determine the estrogenic activity of influent and effluent from an 
optimized pilot-scale CW wastewater treatment method.  
2.   Evaluate the changes in the estrogenic activity of wastewater through the pilot-scale CW 
unit processes. 
3.   Determine how the predicted estrogenic activity of wastewater, derived from chemical 
analysis at various time points of treatment, compares to the activity measured using the 
YES assay for different dose intervals. 
The specific project objectives were achieved by: 
i.   Evaluating the 7 target chemicals (atrazine, estradiol, 4-nonylphenol, DEET, 
carbamazepine, triclosan, and caffeine) for their estrogenic activity individually and in 
mixtures. 
ii.   Evaluating the estrogenic activity of the wastewater entering the pilot-scale CW prior to 
treatment. 
iii.   Using the concept of estrogen equivalents to monitor changes in the estrogenic activity of 
CW-treated wastewater as it moves through the various stages of the pilot-scale wetland 
for each dose interval. 
iv.   Using data from chemical analysis and bioassay-derived data to compare the predicted 





CHAPTER 2: METHODS 
 
2.1 YES Procedure 
 The Yeast Estrogen Screen follows the methods of Routledge and Sumpter (1996) and 
the entire procedure is presented in Appendix A with one modification. YES colonies are 
streaked on solid agar plates prepared from Ura-Trp liquid media instead of solid agar plates 
prepared from growth media because Ura-Trp is a differential and selective media that helps 
prevent contamination of plates by other microbes. The assay is conducted in a 96-deep-well 
plate with samples run in duplicate rows, such that three chemicals can be tested on each plate 
with the final chemical tested being the assay’s positive control, E2. On the first day of the assay 
a single yeast colony isolate is transferred to a 50mL falcon tube containing 7mL of growth 
media, and is allowed to grow in an incubator-shaker for 48 hours at 30°C and 200rpm. On the 
third day of the assay, the YES suspension is diluted with additional growth media to an optical 
density between 0.15- 0.20 using a UV-VIS plate reader set to 620nm (a measure of turbidity 
and, therefore, a surrogate for yeast cell density). The YES dilution is then spiked with a 
0.01g/mL solution of CPRG prepared in laboratory grade water (LGW), such that the ratio of 
CPRG to growth media is 10µL/mL. LGW was prepared using a Dracor Water System unit 
(Durham, NC) which removes residual disinfectants, reduces the total organic carbon (TOC) to  
< 0.2 mg/L C and removes ions to 18 MΩ. LGW that is used to make the 10% ethanol solution, 
the CPRG solution, and all chemical and sample dilutions is also filtered using sterile Corning 





early part of this research of contamination interfering with the assay results. Using a 
multichannel pipette, 100µL of a 10% ethanol 90% LGW solution is added to all wells in 
columns 2-12. Then, 200µL of sample prepared in 10% ethanol 90% LGW is applied to the first 
column in duplicate rows, and serially diluted across columns 1 through 11 using a 1:2 dilution 
factor. Column 12 receives no chemical and contains only 100µL of 10% ethanol solution. All 
wells receive 200µL of the yeast/CPRG solution. Column 12 contains only assay solvent, 
yeast/CPRG and, therefore, acts as the negative control and a check for cytotoxicity. The plate is 
then sealed with plate sealing film and allowed to shake in an incubator-shaker for 5 minutes at 
30°C and 200rpm. The shaker is turned off and the plate left to incubate at 30°C for 48 hours . 
On the fifth day of the assay, 100µL of supernatant is transferred from each well of the 96-deep-
well plate to a 96-flat-well plate and the absorbance of each well at 540nm (wavelength at which 
chlorophenol red maximally absorbs) and 620nm (wavelength used as a turbidity measure) is 
recorded. 
A standard operation procedure (SOP) has been established for testing E2 and 4-
nonylphenol (4-NP) with the YES assay in the Weinberg laboratory and is described in Nunes 
(2013). Atrazine (ATZ), triclosan (TCS), and carbamazepine (CBZ) were tested for estrogenic 
activity up to their solubility limits in water (summarized in Table 1), while caffeine (CAFF) and 
DEET were evaluated up to the millimolar level and no higher because no indication of an 
estrogenic response was observed at those concentrations.  Stocks of each target chemical were 
prepared in ethanol and stored in an upright freezer at -20°C. On the third day of the assay, a 
working solution of each chemical is prepared fresh by performing a 1:10 dilution of the 
chemical stock such that the percentage of ethanol in the working solution does not exceed 10% 





volume of 1mL). The structures of the test chemicals are shown in Figure 3 and the working 
solution concentration for each chemical is summarized in Table 1.  









Triclosan 289.54 a12.0 4.14E-05 4.00E-05 
4-Nonylphenol 220.35 b 6.25 2.84E-05 2.50E-05 
17-b-Estradiol 272.38 c3.90 1.43E-05 5.00E-08 
Atrazine 215.68 d33.0 1.61E-04 1.60E-04 
Carbamazepine 236.27 e18.0 1.11E-01 2.00E-03 
Caffeine 194.19 f1.60E+04 7.62E-05 7.50E-05 
DEET 191.30 g2.00E+03 5.85E-02 2.00E-03 
a European Commission: Scientific Community on Consumer Safety, 2010 
b California Environmental Protection Agency, 2009 
c Pubchem, 2017 
d DeMarini & Hoar Zahm, 1999 
e United States Environmental Protection Agency, 2004 
f Sigma Aldrich, 2017 
g California Environmental Protection Agency, 2000 
 
 
2.2 Target Chemical Data Analysis 
 A corrected absorbance is calculated for each well of the concentration dilution series for 
a given chemical using equation 1: 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑	  𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 𝐴𝑏𝑠/01 − (𝐴𝑏𝑠451 − 𝐴𝑏𝑠451	  678	  9:6;<:=)       (1) 
The value obtained when the absorbance of the negative control at 620nm is subtracted from the 
absorbance of the well at 620nm gives the overall turbidity measure of the sample and is 
subtracted from the absorbance of that same well at 540nm so that only the absorbance of 
chlorophenol red is being measured. Cytotoxicity is monitored by comparing the absorbance 
value of the well at 620nm to the absorbance of the negative control at 620nm. The negative 
control contains no sample, and, thus, any turbidity present in the negative control can be used as 





sample is less than 10% of the negative control, the concentration of that well is said to be 
cytotoxic and is not included in any data analysis.  






































Duplicate absorbance measures of each well are plotted against the log transformed molar 
concentration using GraphPad Prism 4.3 (GraphPad Software; La Jolla, CA), and a sigmoidal 
dose response curve with variable hillslope is fit to the data. GraphPad Software then calculates 
an EC50 for each chemical that gives an estrogenic response. An estrogen equivalent factor 
(EEF), which relates the potency of the EDC to the potency of E2, was calculated for each 






The calculated EEFs were then used in conjunction with chemical analysis data to calculate 
predicted EEQs for each sample, as discussed in section 2.8.  
 
2.3 Wastewater Source 
 The source wastewater used for the column pilot study was collected from the Jordan 
Lake Business Center (JLBC) located in Apex North Carolina, which uses a subsurface vertical 
flow sediment filter as the onsite wastewater treatment. Sewage produced by the approximately 
60 occupants at the business center is collected in a septic tank and then treated through a series 
of subsurface sediment filters, beginning with a bed that is aerobic in nature, followed by a bed 
that is anaerobic, and finishing with a second aerobic sand bed. The volume of source 
wastewater needed for an entire dose interval study was collected from the storage tank in the 
field site prior to the start of each study to ensure uniformity of the column influent, which can 
change over time based on the changes in production of wastewater. Wastewater was stored in 
25L polyethylene containers in a cold room set to 4°C for a maximum of three weeks while one 






2.4 Aerobic and Hypoxic Batch Study 
 In order to better understand the mechanisms of remediation occurring in the pilot-scale 
constructed wetland discussed in section 2.5 below, a batch study was conducted as described in 
Holmes (2017) to analyze the effect of oxygenation on contaminant removal.  Briefly, Stalite 
(discussed in section 2.5 below) was incubated at 25°C with wastewater for two months to 
establish a biofilm on the Stalite, while oxygen was bubbled into the wastewater to ensure proper 
bacterial growth. Then, 60g of the Stalite was transferred into six acid washed 1L amber bottles. 
Wastewater was spiked with the 7 target contaminants to obtain a final concentration of 100µg/L 
of each chemical (this procedure is described in more detail in section 2.5 below), and 600mL of 
spiked wastewater was aliquoted into the bottles containing Stalite. The samples were allowed to 
incubate and shake at 100rpm and 25°C. Prior to incubation, aerobic conditions were developed 
in three of the bottles by flushing them with air until achieving a dissolved O2 reading of at least 
7mg/L, and the samples were then left uncovered to allow for free exchange of gases. Low 
oxygen conditions were developed in the other three bottles prior to incubation by flooding them 
with argon until achieving a dissolved O2 reading of less than 3mg/L and then capping for 
incubation. While this is a higher level of oxygen than is typically found for hypoxic conditions 
(typically defined as 1mg/L of dissolved O2) there were limitations in the system used by 
Holmes (2017) that prevented lower oxygen conditions from being obtained (Martinez-Lavanchy 
et. al., 2015). As a result, a low enough level of oxygen (<3.0mg/L) was obtained that was 
expected to go hypoxic in the column studies and batch study vessels after sealing and 
incubating. For each set of hypoxic and aerobic conditions, one sample was sacrificed for 
chemical and YES analysis after 1 hour, the next after 8 hours, and the final after 24 hours of 





Whatman (Fisher Scientific; Suwanee, Georgia) glass fibre filters followed by a Sartorius (Fisher 
Scientific; Suwanee, Georgia) 0.45µm nylon filter. Samples were then processed via SPE, as 
described in section 2.6.  
2.5 Pilot-Scale Constructed Wetland Set Up 
 The pilot-scale CW was conducted by another student as part of the larger research 
project and is described in detail in Holmes (2017).  The pilot-scale CW utilized large stainless 
steel vertical columns (10 cm x 100 cm) each containing a column of substrate to reproduce a 
subsurface vertical flow wetland in the laboratory and a schematic is presented in Figure 4. The 
columns were packed with Stalite, a slate aggregate produced by rotary kiln processing of 
volcanic ash sediment naturally occurring in North Carolina (Stalite, 2009). Stalite is 
characterized by a high porosity and surface area, making it ideal for colonization of bacterial 
communities. The columns were stored in a cold room set at 4°C (to prevent additional bacterial 
degradation of column effluent in the collection vessel) and wrapped with heating wire set at 
25°C to promote bacterial growth and encourage the development of a biofilm on the Stalite.  
Prior to any experiments, each column was conditioned by closing the effluent port on the 
column and filling it with wastewater. The presence of a biofilm was confirmed using a 
FastDNA Spin Kit for DNA soil extraction (MoBio; Carlsbad, CA) prior to any dosing studies. 
The columns were run in series, with the first column being aerobic in nature, the second being 
hypoxic, and the third being aerobic. Aerobic conditions were developed by leaving the aerobic 
columns uncovered, unlike the hypoxic column which was sealed using a metal cap on the top of 
the column. Hypoxic conditions were developed by flooding the column with argon, which has a 






Figure 4. Schematic of the pilot-scale constructed wetland.  
  
Five different dose interval studies – 8, 12, 24, 36 and 8 hour flooding – were tested to 
determine the relationship between dose interval and target contaminant removal as described in 
Holmes (2017). Wastewater was spiked with each target chemical (ATZ, DEET, 4-NP, CBZ, 
CAFF, E2, and TCS) to yield an overall spike level of 100µg/L for each chemical. Chemical 
stocks, each at 1g/L, were prepared in ACS grade methanol (Honeywell Burdick & Jackson; 
Muskegon, MI) and stored at 4°C. Due to solubility limitations, a stock of 1g/L of caffeine was 
prepared in LGW instead of methanol. Each study was conducted for nine days based on data 
from a previous round of column studies described in Holmes (2017). For each study, a total of 
1.61L of spiked wastewater was poured into the top of the columns daily (over the course of five 
minutes), separated into aliquots based on the dose interval such that the total daily application 
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Table 2. Summary of Pilot-Scale CW Optimization Study Parameters 
 
On the first day of each study, a volume of spiked wastewater (summarized in Table 2) 
was applied only to the first aerobic column and allowed to freely drain into a collection vessel. 
After the first dose interval had passed, the effluent from the aerobic column was poured into the 
top of the hypoxic column and allowed to freely drain into a collection vessel, while a second 
dose was applied to the first aerobic column. After the second interval, the effluent from the 
hypoxic column was transferred to top of the last aerobic column, and after the appropriate dose 
interval the process was repeated. For the 8 hour flooding dose interval, instead of freely 
collecting each column was saturated with wastewater and only allowed to drain at the end of the 
dose interval. Once the wastewater had passed through all three columns (three days for all 
studies except the 36 hour study, which took 4.5 days to pass through the final column), samples 
from column three were collected in 1L amber bottles and stored at 4°C until extraction. On the 
ninth and final day of the study, samples were collected from each column such that the sample 
collected from column 1 had only passed through the first aerobic column, the sample from 
column 2 had passed through the first aerobic and hypoxic columns, and the sample from column 
three had passed through all three columns. Prior to solid phase extraction of wastewater 
samples, 60mL aliquots of wastewater samples were set aside for routine water quality parameter 






Applied Per Dose 
Interval (L) 
Total Wastewater 




8 3 0.537 1.61 24 
12 2 0.805 1.61 24 
24 1 1.61 1.61 24 
36 0.5 1.61 1.61 36 





2.6 Sample Processing 
All materials and chemicals used for SPE are summarized in Appendix B. At the end of 
each study, all samples were filtered using stacked  2.7µm and 1.5µm Whatman glass fibre 
filters, followed by a Sartorius 0.45µm nylon filter, which was replaced as needed due to 
clogging of the filter. 250mL aliquots of each sample were transferred to acid-washed amber 
bottles using a graduated cylinder, and spiked with 12.5µL of a stock of atenolol at 1g/L 
(prepared in methanol) as the surrogate standard for quality control. For each dose interval study, 
duplicate samples of the source wastewater were prepared for characterization of the column 
influent prior to spiking. Four aliquots of the source wastewater prepared with the target 
chemicals spiked in at 5, 10, 50, and 100µg/L were used to build a standard addition calibration 
curve from which quantification of the target chemicals in all samples was achieved. The full 
SPE procedure was originally described by Stanford and Weinberg (2007) with a few 
modifications by Holmes (2017).  Samples that were intended only for chemical analysis were 
eluted from the SPE cartridges into conical vials, blown down using a gentle stream of high 
purity nitrogen and low heat (30°C), and reconstituted in 2mL of methanol, yielding an overall 
concentration factor of 125. Samples that were intended for both chemical and YES analysis 
were processed and eluted from the cartridges using the same method with slight modifications 
to the reconstitution procedure as discussed in the next section.  
 
2.7 Preparation of Samples for YES Analysis  
From the samples processed and eluted as described in section 2.5, unspiked wastewater 
influent, spiked wastewater influent, an intermediate time point in the study, and final day 
samples collected from columns 1,2, and 3, were selected for each dose interval study for 





time. The eluted extracts selected for both chemical and YES analysis were split into two 
aliquots of equal volumes, transferred to conical vials, and blown down to dryness using a gentle 
stream of high purity nitrogen and low heat (30°C). For each eluted sample that was split and 
blown down, one aliquot was reconstituted in 1mL of methanol for chemical analysis while the 
second was reconstituted in 1mL of molecular biology grade ethanol for analysis using the YES 
assay. Separate aliquots are required because ethanol is compatible with the YES assay but not 
chemical analysis.  
All extracts have undergone the same overall concentration factor of 125 from 
wastewater sample to extract.  However, samples that have undergone different levels of 
estrogenic activity removal needed to be differentially diluted in order to see a full dose response 
curve on the YES assay. As a result, the processing of each SPE extract for application on the 
YES assay is different and must be accounted for in data analysis. The unspiked source 
wastewater used for each study had low levels of estrogenic activity to begin with and, therefore, 
was not diluted prior to application on the YES assay. As a result, the unspiked sample had to be 
blown down a second time and reconstituted 1:1 in assay solvent (e.g. 1mL of extract blown 
down and reconstituted in 1mL of 10% ethanol solution). Similarly, for samples that required 
dilution factors less than 1:10 (e.g. 1:4, 1:2), an aliquot was transferred into a conical vial, blown 
down to dryness, and reconstituted in a 10% ethanol to ensure that all working dilutions of the 
extracts were prepared such that the final percentage of ethanol did not exceed 10%. Tables 3 
through 7 summarize the sample identity and required dilution factor for all samples analyzed on 









Table 3. 8 hour Dose Interval Samples and Preparation for YES 
Sample Name Sample Identity Degree of 
Treatment 
Dilution Factor for 
Reconstituted Extract 
T0 Unspiked Source WW Untreated aNo dilution 
T0 Spiked WW + 100µg/L spike of Untreated 1:100 
T3C3* First WW sample collected All 3 columns 1:4 
T8C1 Final WW sample collected Column 1 only 1:20 
T8C2 Final WW sample collected Columns 1 and 2 1:4 
T8C3 Final WW sample collected All 3 columns 1:2 
*T#C$ where: T= Time point 
  #= Sample collection number (i.e. 3 means it was the third sample collected) 
  C= Column  
  $= Column the sample was collected from 
aNo dilution indicates a 1:1 reconstitution into 10% ethanol as described in section 2.6 
 
 
Table 4. 8 hour Flooding Dose Interval Samples and Preparation for YES 
Sample Name Sample Identity Degree of 
Treatment 
Dilution Factor for 
Reconstituted Extract 
T0 Unspiked Source WW Untreated No dilution 
T0 Spiked WW + 100µg/L spike of Untreated 1:80 
T3C3 Fourth WW sample 
collected 
All 3 columns 1:2 
T8C1 Final WW sample collected Column 1 only 1:50 
T8C2 Final WW sample collected Columns 1 and 2 No dilution 
T8C3 Final WW sample collected All 3 columns 1:2 
 
Table 5. 12 hour Dose Interval Samples and Preparation for YES 
Sample Name Sample Identity Degree of 
Treatment 
Dilution Factor for 
Reconstituted Extract 
T0 Unspiked Source WW Untreated No dilution 
T0 Spiked WW + 100µg/L spike of Untreated 1:100 
T3C3 Third WW sample collected All 3 columns No dilution 
T7C1 Final WW sample collected Column 1 only 1:80 
T7C2 Final WW sample collected Columns 1 and 2 1:20 





Table 6. 24 hour Dose Interval Samples and Preparation for YES 
Sample Name Sample Identity Degree of 
Treatment 
Dilution Factor of 
Reconstituted Extract 
T0 Unspiked Source WW Untreated No dilution 
T0 Spiked WW + 100µg/L spike of Untreated 1:100 
T5C3 Second WW sample collected All 3 columns 1:10 
T9C1 Final WW sample collected Column 1 only 1:80 
T9C2 Final WW sample collected Columns 1 and 2 1:20 
T9C3 Final WW sample collected All 3 columns 1:10 
  
 
Table 7. 36 hour Dose Interval Samples and Preparation for YES 
Sample Name Sample Identity Degree of 
Treatment 
Dilution Factor of 
Reconstituted Extract 
T0 Unspiked Source WW Untreated No dilution 
T0 Spiked WW + 100µg/L spike of Untreated 1:100 
T4C1 Final WW sample collected Column 1 only 1:100 
T4C2 Final WW sample collected Column 1 and 2 1:20 
T4C3 Final WW sample collected All  3 columns 1:10 
 
 
2.8 Mixture Analysis of Seven Target Compounds 
 A standard mix of the contaminants was prepared at the concentration that would be 
expected in the SPE extract, which undergoes a 125-fold concentration factor, assuming 100% 
recovery of target analytes (i.e. 12.5mg/L). First, a 12.5mg/L solution was prepared in methanol 
for all contaminants except caffeine, which was prepared in LGW due to solubility limitations. 
The 12.5mg/L mixture was prepared by transferring 125µL of each individual 1g/L stock (in 
methanol) of E2, 4-NP, ATZ, CBZ, DEET, and TCS to a 10mL volumetric flask and filling to 
volume with methanol. A 12.5mg/L solution of caffeine was prepared by transferring 125µL of a 





LGW. A working solution was prepared by diluting this concentrated standard in the same 
manner as the extracts for application on the YES assay. This was done by transferring 13µL of 
the 12.5mg/L dilution of CAFF and 13µL of the 12.5mg/L mix of E2, 4-NP, ATZ, CBZ, DEET, 
and TCS to a test tube, adding 162µL ethanol, and 1320µL LGW and vortexing to mix. This 
mixture was then analyzed in the same manner as the SPE extracts described in section 2.9 to 
calculate the EEQs of the mixture, which was then compared to the sum of the individual 
chemical EEQs. 
2.9 Data Analysis for SPE Extracts 
YES data for the SPE extracts were processed identically to the data for individual 
chemicals, with two exceptions. First, the corrected absorbance was plotted against the volume 
of undiluted SPE extract present in each well as expressed in L/well equivalents (Leusch et. al., 
2010).  Doing so allows for the sample dilution factor to be included in the dose response curve 
and ensures all dose response curve analysis is in terms of the pure extract and not the working 
solution.  For typical analysis of an individual chemical on the YES assay, an EC50 is calculated 
from a plot of absorbance versus chemical concentration, but the same cannot be done for an 
environmental extract of unknown concentration. Instead the absorbance of each well is plotted 
against the volume of undiluted extract in each well and an effective volume 50% (EV50) (i.e. 
the volume of extract producing 50% of the maximal response) is calculated (Leusch et.al., 
2010). EEQ can then be determined using equation 3, which relates the concentration of E2 that 
would produce the half maximal response to the volume of extract that would produce the same 
half maximal response (Leusch et. al., 2010):  
𝐸𝐸𝑄 =
𝐸𝐶50 𝐸2








The EC50 of E2 is reported as the ng/well concentration that corresponds to the half 
maximal response, and the EV50 of the sample is reported as the L/well concentration of the 
undiluted extract, resulting in an EEQ in units of ng/L. This allows for a calculation of total 
estrogenic activity without requiring knowledge of the mixture components. Each extract is 
tested three times by preparing a fresh dilution of an aliquot of the extract on the third day of the 
YES assay. This allows for calculation of an average EEQ and its corresponding standard 
deviation.  
To determine if any of the observed differences in estrogenic activity removal 
efficiencies for batch study samples were statistically significant a Student’s t-test for two 
sample means with unequal variance was conducted in Microsoft Excel at the alpha=0.10 
significance level. As percent reductions are not binary in nature and can take on any value 
between 0% and 100%, a t-test is the most appropriate statistical test (as compared to a z-test 
which is used for binomial variables and proportions). Differences in removal efficiencies were 
determined to be statistically significant when the associated  p-value was less than a=0.10.  
 
2.10. Calculation of Predicted EEQ   
Sample extracts were analyzed for the 7 target chemicals using reverse phase high 
pressure liquid chromatography with detection by tandem mass spectrophotometry (LCMS) in 
electrospray ionization mode as described in Holmes (2017). Individual recoveries of each target 
compound were calculated using a method of standard addition, as described by Holmes (2017), 
and were used to adjust the concentration of the estrogenic targets in predicted EEQ calculations. 
Chemical concentrations are reported as the concentration present in the extract, and not the 





Total predicted EEQs for samples with different concentrations of estrogenic compounds 
required first calculating the EEF for each estrogenic compound using equation 1 and then using 
equation 4 (where n represents a given estrogenic target compound): 






Only species that were determined to be estrogenic on the YES assay during analysis of the 
individual target compounds in the early part of the study are used when calculating a predicted 






CHAPTER 3: RESULTS AND DISCUSSION 
3.1 Individual Target Compound Estrogenic Activity 
 Two of the 7 target compounds, E2 and 4-NP, are known estrogenic chemicals, and their 
estrogenic activity, which is summarized in Table 8, was confirmed by the YES assay. The mean 
and standard deviation EC50 for E2, which is also the positive control for the YES assay, over 
the entire 18 month study was found to be 0.539 ± 0.190	  nM (n=59) and an example dose 
response curve is shown in Figure 5. 
Table 8. Summary of Estrogenic Target Chemical Activity 
 E2 (n=59) 4-NP (n=4) ATZ (n=6) 
Average EC50 (M) 5.39E-10 6.98E-07 3.99E-05 
Standard Deviation (M) 1.90E-10 1.03E-07 1.68E-05 
EEF 1.00 0.000771 0.0000135 
  
The values in Table 8 are on the same order of magnitude as those reported in the literature for 
the YES assay, which range from 0.2nM to 0.25nM for E2 (Arnold, Robinson, Notides, 




















Figure 5. Example YES assay dose response curve for serial dilutions (1.67E-08M to 3.25E-





The average EC50 for 4-NP was found to be 0.698 ± 0.103	  µM (n=4), a value that falls 
in the range reported in the literature for the YES assay, which is 0.35-210µM (Folmar et. al., 
2002; Svobodová, Plačková, Novotná, & Cajthaml, 2009). Atrazine was also found to be 
estrogenic with an average EC50 of 39.9 ± 16.8	  µM (n=6). Example dose response curves for 4-



















Figure 6. Example YES assay dose response curve for serial dilutions of 4-nonylphenol (8.29E-






















Figure 7. Example YES assay dose response curve for serial dilutions of atrazine (5.07E-05M to 






There is conflicting information in the literature regarding the estrogenic activity of 
atrazine and its ability to bind to the human estrogen receptor. Previous research has not found 
atrazine to activate b-galactosidase transcription in the YES assay; however, it was shown to 
inhibit the binding of E2 in a human ERa competitive binding assays with a corresponding 
inhibitory concentration 50% value of 358µM (Bistan, Podgorelec, Marinšek Logar, & Tišler, 
2012; Scippo et al., 2004). This indicates that atrazine is capable of binding to the ER and thus 
has the potential to activate the b-galactosidase pathway, as confirmed in this current study. 
Table 8 summarizes the average EC50 values of the three estrogenic chemicals, along with their 
resultant EEFs which are calculated as described in equation 2 of Chapter 2. While the EC50 of 
E2 is higher in this set of results than other reported research, the resultant EEF of 4-NP 
(0.000771) is still in good agreement with reported literature value of 0.00063, indicating the 
resultant EEFs can still be used to calculate predicted EEQs from chemical analysis data (Zhao 
et. al., 2011).  
Carbamazepine and Triclosan were tested (n=3) up to their limit of solubility in water 
(solubilities given in Table 1 of Chapter 2), and were not found to be estrogenic on the YES 
assay, as shown by the lack of dose response in Figures 1 and 2 of Appendix C. Caffeine and 
DEET were tested (n=3)  up to millimolar levels, nearly two orders of magnitude higher than 
environmental occurrence levels, and showed no induction of b-galactosidase, as seen in Figures 
3 and 4 of Appendix C. Carbamazepine and caffeine have been previously tested on the YES 
assay and there was no detected induction of b-galactosidase activity in those experiments (Fent, 
Escher, & Caminada, 2006). Triclosan has been shown to be antiestrogenic in work involving 
recombinant ovarian cancer reporter gene assays (ER CALUX assays), and, therefore, was not 





was also tested in vivo in recombinant gene assays conducted in nine different fish species, and 
showed little transactivation of any of the nine fish ERa (Miyagawa et. al., 2014). DEET is the 
only compound among the 7 examined in this study here that has not previously been tested for 
its estrogenic activity in a reporter gene system in the literature, and, as such, cannot be 
compared to any biologically relevant results.  
 
3.2 EEQ for the Mixture of the Seven Target Compounds 
 A standard mixture of the 7 target compounds in solvent, prepared at the extract 
concentration assuming 100% recovery of target analytes (i.e. 12.5mg/L), had an average 
experimental EEQ of 10.5 ± 1.79 mg/L and the method comparison results are summarized in 
Table 9. An example dose response curve for the mixture is presented in Figure 8.  
 






































Figure 8. Example YES assay dose response curve for serial dilutions (6.67E-07 L/well to  






The mixture was tested to determine whether the 7 targets exhibited additivity, 
antagonism, or potential synergy when combined in a single sample. A predicted EEQ for the 
mixture is calculated for the sample using equation 4 from Chapter 2, and an example of this 
equation is shown below using the quantified EEFs presented in Table 8 for the three major 
estrogenic components of the mixture (E2, 4-NP, ATZ).   




It is clear from the predicted EEQ (12.51mg/L) that the majority of the estrogenic activity in the 
mixture is caused by the presence of the endogenous hormone, E2. The percent difference in 
EEQ between the predicted (12.5mg/L) and the YES derived EEQ (10.5 ± 1.79 mg/L) is 
approximately 17.8%. A student’s t test for two sample means assuming unequal variances was 
conducted to determine if the predicted and experimentally derived EEQ are significantly 
different. This was done by comparing the three experimental replicate EEQ calculated for the 
mixture (from Table 9) against the predicted value of 12.51 mg/L for each replicate (n=3, 
degrees of freedom= 2) at the a=0.10 significance level. The difference was found to be 
statistically significant (p < 0.10). Since the predicted value is consistently higher than the 
observed value, this indicates antagonism might be occurring in the mixture, which would cause 
the observed activity to be reduced compared to the predicted activity. Antagonism can partially 
be explained by the presence of a known ER antagonist, triclosan, in the mixture, which has 
shown to be antiestrogenic in several estrogen receptor-based bioassays (Ahn et. al., 2008).  In 
addition, the 4-NP used in this study is a technical grade mix of isomers, some of which have 
been shown to be more antiestrogenic than estrogenic in MVLN cell lines utilizing the human 





an ER agonist and antagonist could also account for the lower than predicted activity in the 
mixture.   
 
3.3 Aerobic and Hypoxic Batch Study Results 
 The same source wastewater was used for the aerobic and hypoxic batch studies and, as 
such, the average values of the EEQs for the unspiked and spiked wastewater extracts are 
identical for the two sets of conditions. The results for samples sacrificed for SPE after 1, 8, and 
24 hours of incubation are presented in Tables 10 and 11, respectively. The unspiked wastewater 
extract had an average EEQ of 9.45 ±	  1.98 µg/L, which was elevated to 10.1 ± 1.86 mg/L upon 
spiking with 100 µg/L of each of the 7  target chemicals.  
 
Table 10. Aerobic Batch Study YES Results for SPE Extracts 
Sample 
 
Replicate EEQ Replicate EEQ Replicate EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked 7.55 µg/L 9.31 µg/L 11.5 µg/L 9.45 ±	  1.98 µg/L 
T0 + 100 µg/L 11.7 mg/L 10.7 mg/L 8.02 mg/L 10.1 ± 1.86 mg/L 
1hr  5.28 mg/L 5.78 mg/L 7.45 mg/L 6.17 ± 1.14 mg/L 
8hr  5.71 mg/L 6.63 mg/L 8.71 mg/L 7.01 ±	  1.54 mg/L 
24hr  3.03 mg/L 3.65 mg/L 3.30 mg/L 3.33 ±	  0.307 mg/L 
 
Table 11. Hypoxic Batch Study YES Results for SPE Extracts 
Sample Replicate EEQ Replicate EEQ Replicate EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked 7.54 µg/L 9.31 µg/L 11.5 µg/L 9.45 ±	  1.98 µg/L 
T0 + 100 µg/L 11.7 mg/L 10.7 mg/L 8.02 mg/L 10.1 ± 1.86 mg/L 
1hr  8.06 mg/L 6.38 mg/L 6.31 mg/L 6.92 ± 0.993 mg/L 
8hr  6.27 mg/L 5.07 mg/L 6.07 mg/L 5.80	  ± 0.641 mg/L 







 The removal efficiencies for each batch study time point are calculated from the YES 
derived EEQ and are presented in Table 12. Overall, hypoxic conditions were associated with the 
highest rate of removal (75.6%) of estrogenic activity from a starting EEQ of 10.1 ± 1.86 mg/L 
to a final EEQ of 2.73 ± 0.441 mg/L over the course of 24 hours of incubation time.  
Table 12. Batch Study Removal Efficiencies   
Incubation Time Aerobic Removal (%) Hypoxic Removal (%) p-valuea 
1hr  44.8 38.1 0.218 
8hr  37.2 48.1 0.0858 
24hr  70.2 75.6 0.0628 
a: p-value for a student t test for difference of two samples (aerobic and hypoxic) assuming 
unequal variance at the a=0.10 significance level. 
 
In order to perform the  t test, each replicate EEQ for the aerobic and hypoxic conditions 
was used to calculate three corresponding percent removals (as seen in Table D.1 in Appendix 
D) for each incubation time (1, 8, 24 hours). Then a t-test for two sample means was conducted 
using the replicate percent removals to determine whether the mean removals for the two 
conditions (aerobic and hypoxic) were truly different for each incubation time (n=3, degrees of 
freedom= 2). Hypoxic conditions had higher rates of removal after 8 and 24 hours of incubation 
(48.1% and 75.6%), which are statistically significant (p <0.10). Hypoxic conditions yielded a 
lower rate of removal after 1 hour (38.1%) than aerobic conditions (44.8%) but this difference 
was not found to be statistically significant at any alpha level. As expected, the removal 
efficiency increased with increased incubation time for both conditions, except the aerobic 8 
hour extract, which had a reduced removal efficiency (37.2%) compared to the 1 hour extract. 
Differences in removal efficiencies between the batch studies are a result of the difference 
microbial communities that grow under each set of conditions. Aerobic bacteria dominate under 





in nature. Certain compounds are degraded preferentially under aerobic and anaerobic 
conditions, and, thus, changing the level of oxygenation changes the degradation of the target 
compounds by the biofilm.  
 The predicted (calculated from the sum of the analyte concentrations from LCMS 
analysis) and bioassay EEQ for each extract are summarized in Table 13. The analyte 
concentrations for each extract were adjusted using the individual chemical method recovery 
data (recovery data is summarized in Table D.2 of Appendix D) to calculate the actual analyte 
concentration in the SPE extract prior to calculating predicted EEQ.  Nonylphenol was the only 
target compound detected (LCMS results are summarized in Table D.3 in Appendix D) in the 
unspiked wastewater extract and its presence accounts for 39.3% of the observed estrogenic 
activity based on these calculations. Samples that spend the longest time incubated with the 
Stalite (i.e. 24 hour aerobic and 24 hour hypoxic samples) had very low percentages (0.165% and 
0.207 % respectively) of observed activity that could be predicted from the target analytes. 
Overall, the hypoxic conditions had the lowest percentage of activity that could be predicted 
from the estrogenic compounds targeted in this study for all time points. For all samples, the 
observed activity using the YES assay was much higher than could be predicted from chemical 
analysis, indicating the possible formation of estrogenic metabolites that are not captured in the 
LCMS analysis. This indicates that the YES assay provides additional insight into the estrogenic 
activity of treated wastewater effluent, activity which would be greatly underestimated if 
samples are analyzed only by chemical analysis. Taken together, this indicates that the YES 
assay can be used to track the removal of estrogenic activity through treatment processes, and 






Table 13 Comparison of EEQs for SPE Extracts for the Batch Study from LCMS and YES Data 

























3.71 µg/L 9.45 µg/L 39.3 3.71 µg/L 9.45 µg/L 39.3 
T0 + 100 
µg/L 
1.26 mg/L 10.1 mg/L 12.4 1.26 mg/L 10.1 mg/L 12.4 
1 hour 2.44 mg/L 6.17 mg/L 39.5 94.4 µg/L 6.92 mg/L 1.37 
8 hours 1.42 mg/L 7.01 mg/L 20.3 4.17 µg/L 5.80 mg/L 0.0719 
24 hours 5.48  µg/L 3.33 mg/L 0.165 5.65 µg/L 2.73 mg/L 0.207 
 
3.4. Estrogenic Activity of Column Study Samples   
Activity of Source Wastewater 
 The estrogenic activity of the wastewater prior to being spiked for the column study 
remained fairly consistent throughout the duration of the study. The wastewater used in the 8 and 
36 hour dosing studies was collected from the JLBC CW field site at the same time, which is 
why the EEQ for the unspiked water extracts are identical for those two studies. Overall, the 
EEQ of the unspiked extract was the lowest for the 8hr flooding dose interval (EEQ=  0.861	  ± 
0.139 µg/L) and highest for the 8 and 36 hour dosing studies (EEQ= 2.63 ±	  0.437 µg/L), with 
the others falling somewhere in between. 
 
Activity of the Spiked Extracted Wastewater 
 A predicted EEQ was calculated for the extracted spiked wastewater (i .e. wastewater 
spiked with 100 µg/L of  each chemical and processed through SPE prior to any application on 
the pilot scale CW) used for each dosing study. A predicted EEQ was calculated from the 





equation 5. As with the batch study, the actual concentration of analyte in each SPE extract was 
calculated by adjusting for the individual chemical method recovery data (recovery data is 
summarized in Table D.2 of Appendix D). A comparison of the predicted EEQ with the 
experimental bioassay results is presented in Table 14.  Three of the extracted spiked wastewater 
samples (8 hour, 24 hour, and 36 hour flooding) showed average EEQ much higher than what is 
predicted from chemical analysis at 6.20 ±	  1.92 mg/L for the 8 and 36 hour and 6.90 ± 2.72 
mg/L for the 24 hour dose interval. The remaining two spiked extracts (8 hour flooding, and 12 
hour) had YES assay-derived EEQ one order of magnitude and 50% lower than the predicted 
value, respectively.  YES assay-derived EEQs are a measure of net estrogenic activity (i.e. sum 
of estrogenic activity minus the sum of antiestrogenic activity) of a mixture. As a result, lower 
activity observed using the YES assay indicates that there are likely antiestrogenic compounds 
that are present in the wastewater background that are lowering the observed activity, but are not 
targeted in the LCMS method.  Higher activity that is seen in the extracted spiked wastewater for 
the 8, 24, and 36 hour extracts could be explained by the presence of compounds in the 
background wastewater that influence how the target chemicals behave in a mixture. While the 
activity in these samples is higher than predicted from chemical analysis, it is still lower in all 
samples than the activity observed in standard mixture prepared in solvent (as discussed in 
section 3.2), further supporting the hypothesis that the increased observed activity is the result of 
interference of chemicals in the wastewater matrix and not from interactions occurring between 










Table 14. Comparison of EEQ Calculated from LCMS* and YES# Data for Spiked Wastewater 
Dose Interval EEQ# of Extracted Wastewater 
Spiked at 100 µg/L 
Predicted EEQ* 
8 hour 6.20 ±	  1.92 mg/L 
1.26 mg/L 
8 hour flooding 128± 14.9 µg/L 
12 hour 693 ± 86.6 µg/L 
24 hour 6.90 ± 2.72 mg/L 
36 hour  6.20 ±	  1.92 mg/L 
 *: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
8 Hour Dosing Study 
 The unspiked wastewater for the 8 hour study had an EEQ of 2.63 ±	  0.437 µg/L, which 
was elevated to 6.20 ±	  1.92 mg/L upon spiking of each target compound at 100 µg/L. The 
bioassay derived EEQ values for each SPE extract are summarized in Table 15. Samples 
indicated as T8 are those collected on the final day of the study and the sample denoted as T3 
represents the third column 3 sample collected for this dosing study.  
 









Average EEQ ± 
Standard deviation 
T0 Unspiked  3.12 µg/L 2.29 µg/L 2.49 µg/L 2.63 ±	  0.437 µg/L 
T0 +100µg/L  8.21 mg/L 5.99 mg/L 4.40 mg/L 6.20 ±	  1.92 mg/L 
T8C1 2.70 mg/L 1.90 mg/L 2.63 mg/L 2.40  ± 0.443 mg/L 
T8C2 7.19 µg/L 4.76 µg/L 9.44 µg/L 7.13	  ±	  2.34 µg/L 
T8C3 1.82 µg/L 8.93 µg/L 1.82 µg/L 4.19	   ±	  4.10 µg/L 
T3C3* 4.85 µg/L 1.19 µg/L 4.60 µg/L 7.12 ± 4.14 µg/L 
 *T#C$ where: T= Timepoint 
  #= Sample collection number (i.e. 3 means it was the third sample collected) 
  C= Column  
  $= Column number the sample was collected from 
 
The combined removal of estrogenic activity from the spiked influent applied to column 





T3C3 and T8C3 showed the same overall removal of estrogenic activity, indicating that the 
removal efficiency remained consistent throughout the length of the study. While it is clear that a 
large reduction (61.1%) in EEQ (from an average of 6.20 mg/L to 2.40 mg/L) occurs in the first 
aerobic column, the combined sequence of columns 1, 2, and 3 leads to an overall reduction of 
99.9%. Looking at the relative reductions for each column, it becomes clear that the hypoxic 
column (column 2) facilities the highest reduction in EEQ at 99.7%. The reduction in estrogenic 
activity between column 2 and column 3 is much lower at 41.3%. Table 16 summarizes overall 
and relative removal between columns in this dosing study.  
 
Table 16. 8 Hour Dose Interval Study Removal Efficiencies 
Sample Removal (%) Relative Removal (%) 
T8C1 61.1 61.1 
T8C2 99.9 99.7 
T8C3 99.9 41.3 
T3C3 99.9 N/A 
N/A indicates the relative removal cannot be calculated because the column 2 effluent (i.e. 
column 3 influent) was not characterized for estrogenic activity. Only final day samples 
characterized all three column effluents for their activity.  
  
The predicted EEQ along with the observed bioassay EEQ for each time point are 
compared in Table 17.  None of the estrogenic activity that was observed in the unspiked extract 
could be predicted from the LCMS data as all three estrogenic targets were below detection limit 
(results that are summarized in Table D.4 in Appendix D). For all extracts that had passed 
through at least one column of the CW except T3C3, the percent of activity that could be 
explained from chemical analysis was small, ranging from 0.966% to 9.02%.  This 
underestimation of activity is likely caused by transformation of the parent compounds into their 
metabolites, some of which, such as estrone and estriol (metabolites of E2), are known to be 





exception, and 75.1% of its activity could be predicted from the 4-NP that remained in the 
sample. The difference seen between T3C3 and T8C3 could be explained by an accumulation of 
weakly estrogenic metabolites in column 3 over the course of the study, which would not show 
up in chemical analysis, but could explain why the majority of the activity in T3C3 can be traced 
back to the presence of the target compound, 4-NP, but the activity in T8C3 cannot.   
 
Table 17. Comparison of EEQ for SPE Extracts of 8 Hour Study from LCMS* and YES Data# 
Sample Predicted EEQ* Average EEQ# Percent of Observed Activity 
Explained by the Target 
Estrogenic Analytes 
T0 Unspiked <0.004 µg/L 2.63 µg/L <0.002 
T0 +100µg/L 1.26 mg/L 6.20 mg/L 20.3 
T8C1 217 µg/L 2.41 mg/L 9.02 
T8C2 0.0689 µg/L 7.13 µg/L 0.966 
T8C3 0.0696 µg/L 4.19 µg/L 1.66 
T3C3 5.35 µg/L 7.12 µg/L 75.1 
*: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
8 Hour Flooding Dosing Interval 
 The unspiked wastewater extract for the 8hr flooding dose interval was the least potent of 
all wastewater used for the dosing studies with an average EEQ of 0.861	  ± 0.139 µg/L, which 
was increased to 128 ± 14.9 µg/L upon spiking with each of the target chemicals at 100µg/L. 
The EEQ for each extract are summarized in Table 18. Comparing the EEQ for the extracted 
unspiked wastewater from the different studies indicates that there is variability within the 
background activity of the wastewater, which can explain some of the differences in observed 





used in the 8 hour study is likely caused by the presence of antiestrogenic compounds in the 
wastewater matrix that will reduce the activity observed in the spiked wastewater extract.  
 
Table 18. 8 Hour Flooding Dose Interval YES Results for Solid Phase Extracts 
Sample EEQ EEQ EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked  0.763 µg/L 0.960 µg/L N/A* 0.861	  µg/L 
T0 +100µg/L  141 µg/L 132 µg/L 112 µg/L 128± 14.9 µg/L 
T8C1 1.10 mg/L 2.00 mg/L 1.90 mg/L 1.67 ±	  0.494 mg/L 
T8C2 8.45 µg/L 2.56 µg/L 3.46 µg/L 4.82 ± 3.17 µg/L 
T8C3 2.76 µg/L 2.07 µg/L 2.36 µg/L 2.40 ± 0.344 µg/L 
T3C3 11.4 µg/L 14.1 µg/L 14.2 µg/L 13.2 ±	  1.56 µg/L 
*A third replicate EEQ is not available for the T0 unspiked extract because there was not enough 
sample. As a result a standard deviation cannot be calculated for this sample.  
 
 
The removal efficiency for extracted samples that had passed through all three columns 
increased slightly for the duration of the study, with the removal in T3C3 being 89.7% compared 
to T8C3 which was 98.1%.  The negative removal seen in column 1 (-1200%) could partially be 
explained by selective removal of antiestrogenic compounds or the conversion of antiestrogenic 
compounds into estrogenic compounds in the first column. If antiestrogenic compounds are 
being preferentially removed in column 1 (or converted into species that are estrogenic), it would 
result in an increase of the net activity seen in the YES assay results. Therefore, the majority of 
the removal of estrogenic activity is actually occurring in column 2, which agrees with the 
removal of estrogenic activity observed for column 2 (96.2%) and the high relative removal 
occurring in column 2 (99.7%). Moreover, it becomes clear that the majority of the activity is 
removed in the second column because, while column 3 shows a moderate relative reduction of 
50.3%, column 3 only contributes an additional 1.9% to the overall removal. This data is 






Table 19. 8 Hour Flooding Dose Interval Study Removal Efficiencies 
Sample Removal (%) Relative Removal (%) 
T8C1 -1200 -1200 
T8C2 96.2 99.7 
T8C3 98.1 50.3 
T3C3 89.7 N/A 
N/A indicates the relative removal cannot be calculated because the column 2 effluent (i.e. 
column 3 influent) was not characterized for estrogenic activity. Only final day samples 
characterized all three column effluents for their activity.  
 
The predicted EEQs from the LCMS data in Table D.5. in Appendix D along with the 
bioassay EEQs for the 8hr flooding study are summarized in Table 20. Atrazine and nonylphenol 
were detected in the unspiked wastewater extract and their presence explains 48.2% of the 
activity that was observed using the YES assay (results are summarized in Table D.4 in 
Appendix D). Samples that had passed through column 3 (T3C3 and T8C3) had some of the 
lowest percentages of activity that could be predicted based on the target estrogenic analytes 
(1.70% and 6.08%, respectively). This same phenomenon is seen in the sample from column 2 
(T8C2), which only has 11.0% of its estrogenic activity explained by the predicted EEQs. This 
underestimation of activity is likely caused by the removal of the target chemicals via bacterial 
metabolism into estrogenic metabolites which are not captured by the LCMS analysis used in 
this study. For column 1, however, the percent of activity that could be predicted from chemical 
analysis was quite high at 78.7%, which indicates that there is very little conversion of the target 
compounds into estrogenic metabolites. If column 1 was exhibiting low removal of the 
estrogenic target compounds because it was preferentially removing the antiestrogenic 
compounds in the background wastewater matrix, it would explain both the negative removal in 
activity seen in column 1 and the high percentage of activity that can be explained by the 





agonism) would not be able to be attained from LCMS analysis and, as a result, information 
regarding the selectivity of the columns and the conversion of the parent compounds to their 
metabolites would not be attained without evaluation on the YES assay.  
 
Table 20. Comparison of EEQs for SPE Extracts of 8hr Flooding from LCMS* and YES# Data 
Sample Predicted EEQ* Average EEQ# Percent of Observed Activity 
Explained by the Target 
Estrogenic Analytes 
T0 Unspiked  0.336  µg/L 0.861 µg/L 39.0 
T0 +100µg/L  1.26 mg/L 128 µg/L 980 
T8C1 1.31 mg/L 1.67 mg/L 78.7 
T8C2 0.529 µg/L 4.82 µg/L 11.0 
T8C3 0.146 µg/L 2.40 µg/L 6.08 
T3C3 0.224 µg/L 13.2 µg/L 1.70  
*: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
 
12 Hour Dosing Study 
 
 The average measured EEQ of the unspiked extract was 1.75 ± 0.90 µg/L, which was 
elevated to 693 ± 86.6 µg/L upon spiking of the 7 targets. As was seen in the 8hr flooding study, 
the observed EEQs for the spiked extract are an order of magnitude lower than what is predicted 
from the chemical analysis (1.26 mg/L). As discussed previously, the low EEQ of the spiked 
wastewater extract used in this study is likely caused by the presence of antiestrogenic 
compounds in the wastewater matrix that will reduce the activity observed in the spiked 
wastewater extract. The EEQ calculated for each sample in the 12 hour study is presented in 









Table 21. 12 Hour Dose Interval YES Results for SPE Extracts 
 
 
The combined removal of estrogenic activity from the spiked influent applied to column 
1 after passing through all three columns appears to decrease slightly through the duration of the 
study.  Sample T3C3 had an overall removal of 99.9% while T7C3 showed a slightly lower 
removal at 96.5%. A t test for two sample means assuming unequal variance was run using 
replicate percent differences for the two samples, which are summarized in Table D.6 in 
Appendix D) (n=3, degrees of freedom=2). The difference in percent removal between T3C3 and 
T7C3 were found to be statistically significant at both the a=0.10 and a=0.05 significant level 
(p< 0.05 ). This result indicates that there may be an accumulation of weakly estrogenic 
metabolites in the third column over the course of the study, or that some of the adsorbed 
compounds are sloughing off of the Stalite and returning to the aqueous phase. 
The negative removal seen in column 1 (-476%) could partially be explained by selective 
removal of antiestrogenic compounds or the conversion of antiestrogenic compounds into 
estrogenic compounds in the first column, similar to what was seen for the 8 hour flooding study. 
If antiestrogenic compounds are being preferentially removed in column 1 (or converted into 
species that are estrogenic), it would result in an increase of the net activity seen in the YES 
assay results for column 1. Similar to the results of the 8 hour flooding study, the majority of the 
removal of estrogenic species is actually occurring in column 2, which agrees with the high net 
Sample Replicate EEQ Replicate EEQ Replicate EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked  1.12 µg/L 2.39 µg/L 2.46 µg/L 1.99 ± 0.755 µg/L 
T0 +100µg/L  609 µg/L 689 µg/L 782 µg/L 693 ± 86.6 µg/L 
T7C1 6.90 mg/L 2.29 mg/L 2.81 mg/L 3.99 ± 2.53 mg/L 
T7C3 13.2 µg/L 10.4 µg/L 15.4 µg/L 13.0  ± 2.52 µg/L 





and relative removals in EEQ observed for column 2 (96.5% and 99.4%, respectively). As was 
the case with the 8 hour study, the majority of the activity is removed in the second column 
because, while column 3 shows a moderate relative reduction of 46.6%, column 3 only 
contributes an addition 1.6% to the overall removal, data that is summarized in Table 22.  
 
Table 22. 12 Hour Dose Interval Study Removal Efficiencies 
Sample Removal (%) Relative Removal (%) 
T7C1 -476 -476 
T7C2 96.5 99.4 
T7C3 98.1 46.6 
T3C3 99.9 N/A 
N/A indicates the relative removal cannot be calculated because the column 2 effluent (i.e. 
column 3 influent) was not characterized for estrogenic activity. Only final day samples 
characterized all three column effluents for their activity.  
 
The EEQ predicted from chemical analysis along with the bioassay EEQs for the 12hr 
study are summarized in Table 23. Nonylphenol was the only estrogenic target detected in the 
unspiked wastewater extract but its presence explains only 3.43% of the activity that was 
observed using the YES assay (results that are summarized in Table D.7 of Appendix D). As 
with the previous two studies, samples that had passed through all three columns (T3C3 and 
T7C3) had a low percent of activity that could be predicted based on the target estrogenic 
analytes (13.8% and 0.838%, respectively), likely due to metabolism of target compounds into 















Table 23. Comparison of EEQs for SPE Extracts of 12 Hour Study from LCMS* and YES Data# 
Sample Predicted EEQ* Average EEQ# Percent of Observed Activity 
Explained by the Target 
Estrogenic Analytes 
T0 Unspiked 0.683 µg/L 1.99 µg/L 3.43 
T0 +100µg/L 1.26 mg/L 693 µg/L 181 
T7C1 319 µg/L 4.00 mg/L 7.99 
T7C2 0.0832 µg/L 24.3µg/L 0.342 
T7C3 0.0109 µg/L 13.0 µg/L 0.838 
T3C3 0.0941 µg/L 0.684 µg/L 13.8 
*: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
 
24 Hour Dosing Study 
The unspiked wastewater extract had an EEQ measured by the YES assay of 2.16 ± 
0.801 µg/L, which was elevated to 6.901 ± 2.72 mg/L after it was spiked with 100 µg/L of each 
of the 7 target chemicals. The removal efficiency of the 24 hour study (Table 25) stayed 
consistent during the duration of the study with the removal for T5C3 and T9C3 being 97.7% 
and 98.0%, respectively. The EEQs for each sample are summarized in Table 24 and the removal 
efficiencies are presented in Table 24. Both the overall removals and the relative removals 
increased for each successive column, with the final column having the highest overall relative 
removal efficiency at 85.2%. Unlike previous studies, column 3 facilitated an appreciable 
increase in removal, increasing the net removal of the CW by 11.6%. This same trend is not seen 
in the previous dosing intervals, indicating the removal efficiency of each column may depend 










Table 24. 24 Hour Dose Interval Study YES Results for Solid Phase Extracts 
 Sample Replicate EEQ Replicate EEQ Replicate EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked  2.73 µg/L 1.24 µg/L 2.50 µg/L 2.16 ± 0.801 µg/L 
T0 +100µg/L  3.82 mg/L 12.6 mg/L 7.95 mg/L 6.90 ± 2.72 mg/L 
T9C1 3.16 mg/L 3.86 mg/L 3.75 mg/L 3.53 ± 0.374 mg/L 
T9C2 970 µg/L 1320 µg/L 1080 µg/L 1.12 ± 0.181 mg/L 
T9C3 135 µg/L 336 µg/L 160 µg/L 210 ± 110 µg/L 
T5C3 270 µg/L 98.0 µg/L 188 µg/L 185 ± 86.1 µg/L 
     
Table 25. 24 Hour Dose Interval Study Removal Efficiencies 
 Sample Removal (%) Relative Removal (%) 
T9C1 52.9 52.9 
T9C2 86.4 71.2 
T9C3 98.0 85.2 
T5C3 97.7 N/A 
N/A indicates the relative removal cannot be calculated because the column 2 effluent (i.e. 
column 3 influent) was not characterized for estrogenic activity. Only final day samples 
characterized all three column effluents for their activity.  
 
The predicted and bioassay EEQs for the 24 hour study are compared in Table 26. As 
with the 12 hour dosing interval, nonylphenol was the only estrogenic target chemical detected in 
the unspiked wastewater extract and its presence explains only 10.6% of the activity that was 
observed using the YES assay (results that are summarized in Table D.8 of Appendix D). As 
with other dosing intervals, the percentage of activity that could be predicted from chemical 
analysis was lowest for samples that were treated through all three columns (T5C3, T9C3) and 
were still quite low for column 1 and 2 samples. The consistent underestimation of activity by 
chemical analysis across all studies indicates that microbial metabolism, and not just sorption, is 
facilitating the reduction in EEQ. The consistent underestimation of estrogenic activity predicted 
from chemical analysis in all dosing studies underscores the value that a biological screening tool 





chemical analysis is not sufficient to capture the toxicological risk of an environmental sample, 
and points to the need to evaluate samples with a widely available bioassay, such as the YES.   
 
Table 26. Comparison of EEQs for SPE Extracts of 24 Hour Study from LCMS* and YES Data# 
Sample Predicted EEQ Average EEQ Percent of Observed Activity 
Explained by the Target 
Estrogenic Analytes 
T0 Unspiked  0.185 µg/L 2.16 µg/L 8.60 
T0 +100µg/L  1.26 mg/L 8.10 mg/L 33.2 
T9C1 430 µg/L 3.59 mg/L 11.9 
T9C2 693 µg/L 1.12 mg/L 6.17 
T9C3 12.1 µg/L 210 µg/L 5.75 
T5C3 10.6 µg/L 185 µg/L 5.73 
*: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
36 Hour Dose Interval 
 As mentioned previously, the wastewater used for the 36 hour study was collected at the 
same time as the 8hr study and so the average EEQ for the unspiked and spiked wastewater 
samples are identical at  2.63 ± 0.437 µg/L and 6.20 ±	  1.92 mg/L, respectively. The EEQ for 
each sample is summarized in Table 27. Samples coded as T4 were the final samples collected 
for the 36 hour study. The 36 hour dose interval had the lowest overall removal of estrogenic 
activity at 96.2%. The same trend that was observed in the 24 hour dosing interval, which saw 
the net removals increase steadily with treatment by each successive column, was seen in this 
study with the column 2 and 3 increasing the net removal by 49.8% and 11.6%, respectively. 
This phenomenon is not seen in the shorter dose intervals. However, as with all studies, column 







Table 27. 36 Hour Dose Interval Study YES Results for Solid Phase Extracts 
 Sample Replicate EEQ Replicate EEQ Replicate EEQ Average EEQ ± 
Standard deviation 
T0 Unspiked  3.12 µg/L 2.29 µg/L 2.49 µg/L 2.63 ± 0.437 µg/L 
T0 +100µg/L  8.21 mg/L 7.17 mg/L 4.89 mg/L 6.20 ±	  1.92 mg/L 
T4C1 5.02 mg/L 5.98 mg/L 4.86 mg/L 5.29 ± 0.608 mg/L 
T4C2 1.02 mg/L 1.17 mg/L 1.56 mg/L 1.25 ± 0.283 mg/L 
T4C3 0.191 mg/L 0.376 mg/L 0.360 mg/L 0.309 ± 0.102 mg/L 
 
 
Table 28. 36 Hour Dose Interval Study Removal Efficiencies 
 Sample Removal (%) Relative Removal (%) 
T4C1 34.8 34.8 
T4C2 84.6 76.4 
T4C3 96.2 75.3 
 
The predicted and measured bioassay EEQs for the 36 hour study are compared in Table 
29. Concentrations used to calculate predictions are presented in Table D.9 in Appendix D. 
Atrazine was the only estrogenic target detected in the unspiked wastewater extract and its 
presence explains only 0.01% of the activity that was observed using the YES assay. As with the 
previous dosing studies, the presence of target analytes explains very little of the observed 
activity in samples that passed through column 2 and column 3 (T4C2 and T4C3). Column 1 had 
a higher percent of activity (12.8%) that could be explained by chemical analysis as compared to 
the other columns, likely due to the reduced rate of removal of estrogenic activity observed in the 












Table 29. Comparison of EEQs for SPE Extracts of 36 Hour Study from LCMS* and YES# Data 
Sample Predicted EEQ Average EEQ Percent of Observed Activity 
Explained by the Target 
Estrogenic Analytes 
T0 Unspiked  0.00155 µg/L 2.63 µg/L 0.059 
T0 +100µg/L  1.26 mg/L 6.20 mg/L  20.3 
T4C1 6.79 mg/L 5.29 mg/L 12.8 
T4C2 0.0437 µg/L 1.25 mg/L 0.003 
T4C3 0.0347 µg/L 309 µg/L 0.01 
*: Indicates predicted EEQs calculated from the chemical concentrations in the extracts as 
determine by LCMS. 
#: Indicates EEQs calculated from YES assay response to the extract.  
 
3.5 Discussion 
 The results of the five dosing studies indicate that the removal of estrogenic activity 
decreases as the length of the dosing interval increases, as can be seen in Figure 9. Overall, the 8 
hour and 8 hour flooding dose intervals have the best overall removal at 99.9% and 98.5% 
respectively, but even the worst performing 36 hour dose interval still had high removal at 
96.2%. However, small changes in removal efficiency can lead to significant differences in 
effluent activity with the best performing dose intervals having final estrogenic activities two 
orders of magnitude lower than that of the worst performing intervals: 4.19	   ±	  4.10 µg/L and  
2.40 ± 0.344 µg/L in SPE for the 8 hour studies as compared to 210 ± 110 µg/L 309 ± 102 µg/L 
for the 24 hour and 36 hour studies respectively.  
 Table 30 summarizes the chemical removal for each column as calculated from the 
LCMS analysis (Holmes, 2017). The 24 and 36 hour studies showed the worst removal of E2 
(66% and 48%, respectively) which explains the low removal of EEQ observed in column 1 






Figure 9. Overall estrogenic activity removals for the dosing intervals as calculated using YES 
assay-derived EEQ values.  
 
 
The removal in EEQ for the best performing 8 hour dose interval in column 1 (61.1%) 
also tracked with the high removal of E2 in the first column (88.4%). However, column 1 from 
the 8 hour flooding and 12 hour showed negative removals of EEQ (i.e. an increase in estrogenic 
activity) despite having high rates of removal of E2 (³ 95% and 73% respectively). This 
phenomenon could be caused by a preferential removal of antiestrogenic activity in column 1, 
which is not captured in the LCMS analysis, in conjunction with the conversion of E2 into its 
less potent estrogenic metabolites. The presence of antiestrogenic compounds in the source water 
would cause the EEQ of the extracted spiked source water to be depressed relative to the column 
1 extracts, causing a negative removal of EEQ. The removal of such compounds in conjunction 
with the conversion of E2 into its metabolites would cause the net activity of column 1, as 
































Table 30. Removal Efficiencies of Estrogenic Analytes Calculated from LCMS Data 
Dose Interval 
(h) Column ATZ (%) E2 (%) NP (%) 
8 Flooding 
1 38 ≥ 95 ≥ 95 
2 -1.6 ≥ 99.9 92 
3 -2.4 ≥ 99.9 ≥ 95 
3 (Avg) n=16 3.3 ± 9.5 ≥ 99.9 ≥ 95 
8 
1 20 84 ≥ 95 
2 27 ≥ 99.9 ≥ 95 
3 27 ≥ 99.9 ≥ 95 
3 (Avg) n=16 27 ± 6.0 ≥ 99.9 89 ± 13 
12 
1 4.1 73 ≥ 95 
2 13 ≥ 99.9 ≥ 95 
3 5 ≥ 99.9 ≥ 95 
3 (Avg) n=14 10 ± 5.4 ≥ 99.9 ≥ 95 
24 
1 11 66 74 
2 24 95 94 
3 56 ≥ 98 ≥ 98 
3 (Avg) n=12 46 ± 18 ≥ 98 95 ± 3.8 
36 
1 -14 48 94 
2 19 ≥ 95 ≥ 95 
3 18 ≥ 95 ≥ 95 
3 (Avg) n=8 30 ± 10 ≥ 95 ≥ 95 
 
 Nonylphenol had high rates of removal in extracts from all 3 columns at ³ 95% except 
for some of  24 hour study extracts, while atrazine had low removal in all of the column 1 
samples, ranging from 4.1% to 38%. However, atrazine is nearly five orders of magnitude less 
potent than E2, and its presence in column 1 extracts only accounts for a small fraction of the 
observed EEQ in all column 1 extracts. This indicates that in addition to the low removal of 
atrazine, conversion of target analytes into estrogenic compounds of lower potency must be 
occurring.  
 For the dosing intervals that yielded the best overall reduction in EEQ after treatment by 
all three columns (8 hour, 8 hour flooding, and 12 hour), E2 could not be detected in any of the 
column 2 or column 3 samples. This was not due to failure of the method, as E2 was detected in 





between peak area and concentration. As a result, removals of E2 are estimated to be ≥ 99.9% for 
those samples, and the high removal for E2 is reflected in the high reduction of EEQ. The 
removal of E2, 4-NP, and ATZ for the less efficient dose intervals (24 and 36 hour) increased 
steadily between columns 1, 2, and 3, which tracks with the increased removal efficiency of each 
column as seen in the YES assay. While the removal of 4-NP was equally high, ATZ actually 
had higher rates of removal for all columns for the 24 and 36 hour dose intervals. However, the 
removal of ATZ has less of an impact on the observed EEQ than 4-NP or E2 due to its lower 
potency. Moreover, while removal of E2 was still high (≥ 98% and ≥ 95% for the column 3 
averages of the 24 and 36 hour studies, respectively), E2 was still detected in all three column 
extracts for those studies. Thus, it is likely the reduced removal of E2 that is causing the column 
3 EEQs of the 24 and 36 hour studies to be two orders of magnitude higher than the best 
performing studies, in which E2 could not be detected.  
For all dosing studies, the highest net removal in activity was achieved in the second 
column, as seen in Figure 10.  Column 1 for the 8 hour flooding and 12 hour dosing intervals had 
negative reductions in estrogenic activity, which is likely caused by selective removal of 
antiestrogenic compounds in columns 1, followed by selective removal of estrogenic compounds 
in column 2. Looking solely at the net reductions observed in each column does not tell the 
whole story, however, and it becomes necessary to look at the relative removal efficiency of each 






Figure 10. Cumulative removal efficiencies as calculated using YES assay-derived EEQ values, 
by column. Note, column 1 data from the 8hr flooding and 12 hour dose interval has been 
excluded due to the negative removals observed.  
 
In terms of column efficiency, two patterns arise regarding chemical degradation and 
estrogenic activity removal, which appear to be dependent on the length of the dose interval 
employed. For the shorter 8 hour, 8 hour flooding and 12 hour studies, the hypoxic column had 
the highest overall reduction of estrogenic activity relative to the its column influent. The longer 
dosing intervals do not obey this same pattern. In the 24 hour and 36 hour studies, the relative 
removals steadily increased in each column. Taken together, this information indicates that even 
when there is a large reduction in the first column, the second and third columns continue to 
reduce the estrogenic activity of the wastewater and contribute to the overall reduction in 
activity. In either case, higher net removals (99.9% in the best performing 8 hour study) are 
achieved by utilizing the columns in series. For the 24 hour dosing study, the net removal 
increased 33.5% from column 1 (52.9%) to column 2 (86.4%), and 11.6% from column 2 to 



























looking at the 36 hour study, in which the net removal increased 49.8% from column 1 (34.8%) 
to column 2 (84.6%) and 11.6% in column 3.  
 
 
Figure 11. Relative removal efficiencies of each column for five pilot-scale CW dosing intervals 
as calculated using YES assay derived EEQ values 
 
 
 The results from the batch study also indicate that the efficiency of the column 
conditions, aerobic or hypoxic, will depend on the length of contact time between the wastewater 
and the biofilm. As seen in Figure 12, aerobic conditions yield a slightly higher reduction in 
estrogenic activity during shorter periods of incubation (1 hour) than do hypoxic conditions, 
although these differences are not statistically significant at the a=0.10 significance level. 
However, hypoxic conditions yield higher rates of removal after 8 and 24 hours of incubation, 
and these results were found to be statistically significant (p<0.10). Therefore, it appears that the 
efficiency of each set of conditions are dependent on the dosing interval employed, and the need 
to have two aerobic or two hypoxic stages of the CW may depend on the dosing parameters that 































Figure 12. Comparison of removal efficiencies for the aerobic and hypoxic batch studies, as 
calculated using the YES assay. * indicates statistically significant difference in removal 
(a=0.10). 
 
 When comparing predicted and YES assay-derived EEQs across all samples, targeted 
chemical analysis appears insufficient for predicting the activity of complex environmental 
samples. Of the 37 SPE extracts tested on the YES assay, 35 of them had observed activity that 
was much higher than could be predicted from the concentrations of the three estrogenic target 
compounds, E2, 4-NP, and ATZ. This indicates that the majority of the activity of the sample 
was from other chemicals not targeted in this analysis. The remaining two samples had predicted 
activities that were higher than the activity observed on the YES assay, which can be caused by 
the presence of the triclosan, a known antiestrogenic species, in addition to other antiestrogenic 
compounds present in the background wastewater. The consistent underestimation of activity, 
confirms that chemical analysis alone is an insufficient method to monitor estrogenic activity of 
complex environmental samples. Moreover, it confirms the benefit of using a widely available 
bioassay, such as the YES, to screen environmental samples and track pollutant removal 
































CHAPTER 4: CONLCUSIONS AND FUTURE WORK 
4.1 Conclusions 
The primary objective of this research was to demonstrate how the YES assay could be 
used to estimate the estrogenic activity of influent wastewater and track the removal of that 
activity as the wastewater was treated through the various stages of the pilot-scale CW. While 
there have been efforts to look at the ability of CW to remove emerging contaminants, and thus 
remediate polluted wastewater, this study attempts to correlate the removal of the contaminants 
with a biologically relevant endpoint. The second major objective was to be able to predict the 
estrogenic activity from chemical analysis and compare it to the YES assay-derived activity. 
Doing so would further validate the utility of using a biological assay, in conjunction with 
traditional approaches, to better estimate the activity of wastewater effluent, monitor the 
effectiveness of different treatments and reduce downstream exposure.  
The yeast estrogen screen was able to confirm the estrogenic activity of three (E2, ATZ, 
4-NP) of the 7 emerging contaminants used in this pilot study. Evaluation of the mixture of all 7 
target compounds in solvent indicated that there was possible antagonism occurring in the 
mixture, which is likely caused, but not confirmed, by the presence of the known ER against, 
triclosan.  
 Wastewater collected over the course of several months from the constructed wetland at 
the JLBC in Apex, NC showed levels of estrogenic activity with EEQ ranging from 0.861 µg/L 
to 9.45 µg/L. Taking into account the concentration factor (125) allows for a  rough 





would be in the range of 6.89 ng/L to 75.6 ng/L. However, it is important to note that these 
values only represent an approximation of the wastewater’s activity because chemical recovery 
through the SPE method can only be calculated for the target compounds, and thus might such a 
calculation may underestimate the activity in the source wastewater. The EEQ represent the 
equivalent concentration of E2 that would be required to produce the same overall activity that is 
observed for the wastewater samples. In a study looking at estrogenic activity of sewage 
treatment in Australia and New Zealand, the EEQ of raw sewage samples ranged from 15 ng/L 
to 185 ng/L and conventionally treated effluent had EEQ ranging from 6.0 ng/L to 143 ng/L 
(Leusch et. al., 2006), indicating the JLBC is achieving similar rates of removal as municipal 
wastewater treatment.  
  Adding 100 µg/L of each of 7 chemicals to this wastewater prior to the laboratory studies 
elevated the EEQ by two to three orders of magnitude and allowed for careful monitoring of the 
effect of treatment on their remediation by both the YES assay and LCMS analysis. Treatment of 
the wastewater through sequential columns containing the same solid substrate as used at JLBC 
with either hypoxic or aerobic conditions was able to reduce the EEQ to near background levels 
in all but the 24 and 36 hour dosing intervals.  The effectiveness of the columns was highest for 
the 8 hour dosing interval and decreased as the length of the dosing interval increased. Two 
studies, the 8 hour flooding and 12 hour, indicated that column 1 might have been preferentially 
removing antiestrogenic activity, causing the calculated percent removals to be negative. This 
could be confirmed by further investigation with the YES assay. The YES assay could be used to 
evaluate antiestrogenic activity, as well as estrogenic activity, by co-exposing the yeast to a 





dilution curve. This would allow for the calculation of an inhibitory concentration 50%, much 
like what is calculated for the competitive binding receptor assays.  
  For all studies except the 8 hour dose interval, hypoxic conditions were associated with 
better removal efficiencies and contributed to significant reductions in EEQ. This phenomenon 
was confirmed in isothermal batch studies where hypoxic conditions showed higher rates of 
removal after 8 and 24 hours of incubation, and these differences were found to be statistically 
significant (p < 0.10).  
 The removal of estrogenic activity from the spiked wastewater tracked most 
closely with that of the most potent estrogenic species, E2, whose removal was highest in the 8 
hour, 8 hour flooding, and 12 hour dosing studies. Since E2 is so much more potent than the 
EDCs tested in this study (and most other EDCs), dose intervals that maximize the removal of 
E2 should be used in operation of the CW if the overall goal is to optimize such a system for 
estrogenic activity removal. Such operations would, therefore, need to utilize shorter dosing 
intervals, such as the 8 hour dosing interval, to achieve maximum removal of E2. However, 
estrogenic activity still persisted at low levels even when E2 could not be detected in final 
effluent samples, which is likely the result of conversion of E2 into its less potent but still 
estrogenic metabolites. Background levels of estrogenic activity persisted even after most of the 
parent compound was removed, and may require the addition of a second hypoxic stage to the 
CW to further reduce the activity in the effluent. Overall, the results of the study indicate that a 
restructuring of the current order of the treatment system to allow for two phases of hypoxic 






The presence of the target analytes detected by LCMS could only explain low 
percentages of the total observed activity. In 35 out of 37 of the samples analyzed, chemical 
analysis consistently underestimated the activity of the sample, resulting in predicted EEQ often 
orders of magnitude lower than were observed using the YES. On the other hand, two samples 
overestimated the activity in the extracts, likely due to the presence of antiestrogenic species, 
whose presence would reduce the observed net activity. Taken together, this information shows 
that chemical analysis alone is insufficient to monitor a toxicological endpoint, such as 
estrogenic activity. This further suggests that bioassays can act as useful screening tools, 
especially when conducting studies to optimize water treatment for hazard reduction.  
 
4.2 Future Work 
Future expansions of this work should include evaluating and quantifying both the 
estrogenic and antiestrogenic activity of target compounds being spiked into the wastewater. If 
the ultimate goal is to be able to predict the activity of environmental samples from chemical 
analysis, this work could be expanded to quantify the potency of these major estrogenic 
metabolites and include these estrogenic metabolites in future chemical analysis. However, there 
is a limit to the number of compounds that it is feasible to target in chemical analysis, which is 
why bioassay analysis can prove useful. In addition, column extracts could also be evaluated for 
their antiestrogenic activity using the YES assay, which would provide further insight into 
potential preferential removal of activity (antiestrogenic or estrogenic) occurring in the different 
stages of the CW.  
As mentioned previously, hypoxic conditions showed better removals of estrogenic 





could facilitate increased removal of estrogenic activity. Future work could explore the removal 
efficiency of a CW utilizing a hypoxic column, followed by an aerobic column, followed by a 
second hypoxic column and compare the removal efficiencies seen in the best performing dosing 
intervals. Given the sensitivity of many aquatic species to potent estrogens, even small increases 
in the removal of estrogenic activity by a treatment method can have a protective effect on 
wildlife in receiving waters by helping to reduce their exposure to estrogenic activity.  
A limitation of this study was testing the effectiveness of the CW on removal of target 
compounds and estrogenic activity from a single wastewater matrix. The wastewater used in the 
present study had already been treated by the JLBC CW and, as a result, is cleaner and has a 
reduced organic carbon load than other water types. Therefore, it would be interesting to see if 
this system would continue to achieve high rates of removal of estrogenic activity for a range of 
influent waters. This would provide a stronger case for using CWs to treat a wide variety of 
water types. In addition, this study only examined one relevant toxicological endpoint 
(estrogenic activity). Future work could expand to include other forms of endocrine activity, 
including antiestrogenic activity, and (anti)-androgenic activity, which can also pose a threat to 






APPENDIX A: YEAST ESTROGEN SCREEN (YES) ASSAY PROTOCOL  
 
Part 1: Materials needed 
 
UV-VIS 96-well plate reader (Molecular Devices, EMAX; Sunnyvale, California) 
Shaking Incubator (Shel Lab; Cornelius, Oregon)  
Weighing scale (Sartorius; Goettingen, Germany) 
Disposable sterile vacuum filter/storage system (Corning Incorporated; Corning, New York) 
Disposable (100 x 15 mm) sterile petri dishes (Fisher Scientific; Suwanee, Georgia) 
Disposable 96-flat well bottom microplates (Fisher Scientific; Suwanee, Georgia) 
Disposable 96-deep well 1 mL plates (Fisher Scientific; Suwanee, Georgia) 
Disposable Reagent Reservoirs (VWR; Radnor, Pennsylvania) 
50mL Falcon tubes (Fisher Scientific; Suwanee, Georgia) 
Test tubes (Fisher Scientific; Suwanee, Georgia) 
Plate Sealing Film (Corning Incorporated; Corning, New York) 
Vortex mixer (Barnstead/Thermolyne; Dubuque, Iowa) 
Original potable pipette aid (Drummond Scientific; Broomall, Pennsylvania) 
50 – 300 µL 8 multichannel pipettor (Thermo Labsystems; Vantaa, Finland) 
100 – 1000 µL pipettor (Fisher Scientific; Dubuque, Iowa) 
Disposable (1 – 250 µL) pipette tips (Fisher Scientific; Suwanee, Georgia) 
20 -200 µL pipettor (Pipetman; Middleton, Wisconsin) 








Part 2: Chemicals Needed 
Chemical                    CAS #                    Brand/Source used by Weinberg lab 
aKH2PO4     7778-77-0             Fisher Scientific; Fair Lawn, NJ 
Ammonium sulfate    7783-20-2  Mallinckrodt; Paris, KY 
bKOH      71769-53-4  Fisher Scientific; Fair Lawn, NJ 
Casamino acids    65072-00-6  Fisher Scientific; Fair Lawn, NJ 
Adenine     73-24-5  Alfa Aesar; Ward Hill, MA 
Bacto agar     2014-03-31  BD; Sparks, MD 
cFe2(SO4)3     10028-22-5  MP Biomedicals; Santa Ana, CA 
D (+) Glucose     50-99-7  Fluka; St. Louis, MO 
L-aspartic acid     56-84-8  MP Biomedicals; Santa Ana, CA 
L-threonine     72-19-5  Acros Organics; New Jersey, NJ 
dMgSO4 * 7H2O    10034-99-8  Acros Organics; New Jersey, NJ 
eCuSO4 * 5H2O    7758-98-7  Sigma Aldrich; St. Louis, MO 
fCPRG      99792-79-7  Sigma Aldrich; St. Louis, MO 
Thiamine     59-43-8  Sigma Aldrich; St. Louis, MO 
Pyridoxine     65-23-6  Sigma Aldrich; St. Louis, MO 
D-pantothenic acid hemicalcium salt  137-08-6  Sigma Aldrich; St. Louis, MO  
Inositol     87-89-8  Acros Organics; New Jersey, NJ 
Biotin      58-85-5  Kodak; Rochester, NY 
gDifco yeast nitrogen base  2014-11-30  BD; Sparks, MD 
Adenine Sulfate   321-30-2  Acros Organics; New Jersey, NJ 
Dextrose Anhydrous   50-99-7  Fisher Scientific; Fair Lawn, NJ 
17-b-Estradiol  (98.1%)  50-28-2  Sigma Life Sciences; St. Louis, MO 
4-Nonylphenol (technical grade) 84852-15-3  Aldrich Chemistry; St. Louis, MO 
Atrazine (99.1%)   613-068-00-7  Fluka Sigma Aldrich; St. Louis, MO 
Caffeine Anhydrous   58-08-2  Fluka Sigma Aldrich; St. Louis, MO 
Carbamazepine (99%)  298-46-4  Acros Organics; Geel, Belgium 
hDEET (98.1%)   134-62-3  Fluka Sigma Aldrich; St. Louis, MO  
Triclosan    3380-34-5  Sigma Aldrich; St. Louis, MO 
Ethanol (Molecular Biology Grade) 64-17-5  Fisher Bioreagents; Geel, Belgium 
aKH2PO4: Potassium dihydrogen phosphate 
bKOH pellets: Potassium hydroxide  
cFe2(SO4)3: Iron (III) sulfate 
dMgSO4 * 7H2O: Magnesium sulfate septahydrate 
eCuSO4 * 5H2O: Cupric sulfate pentahydrate 
fCPRG: chlorophenol red-β-D-galactopyranoside 










Part 3: Preparation of solutions and buffers 
Minimal Medium (1L) + L-aspartic acid + L-threonine 
-   Dissolve the following components in 1L LGW 
-   13.61 g KH2PO4 
-   1.98 g (NH4)2SO4 
-   4.2 g KOH pellets 
-   0.2 g MgSO4 * 7H2O 
-   6.72 g casamino acids 
-   Add 1 mL of 10 mg/L Fe2(SO4)3 (prepared just before making the media), 27.4 mL L-
aspartic acid solution and 8.7 mL L-threonine solution 
 




L-aspartic acid solution (4 mg/mL) for the assay medium 
-   Dissolve 0.120 g L-aspartic acid in 30 mL of LGW 
-   Filter sterilize using a disposable filter/storage sterilization system and store at 4°C 
 
 
L-threonine solution (24 mg/mL) for the assay medium 
-   Dissolve 0.240 g L-threonine in 10 mL of LGW 
-   Filter sterilize using a disposable filter/storage sterilization system and store at 4°C 
 
 
D (+) Glucose (20% solution) for the preparation of the growth media 
-   Dissolve 40.00 g glucose in 200 mL LGW 








Copper (II) sulfate (20mM) for the preparation of the growth media 
-   Dissolve 0.128 g CuSO4 * 5H2O in 40 mL LGW 




Vitamin solution for the preparation of the growth media 
-   Using a microbalance, weigh out the following: 
-   8 mg thiamine 
-   8 mg pyridoxine 
-   8 mg D-pantothenic acid hemicalcium salt  
-   40 mg inositol 
-   Dissolve in 180 mL of LGW 
-   Add 20 mL biotin (2 mg/100 mL LGW) 
-   Filter sterilize using a filter/storage sterilization system and store at 4°C 
 
Chlorophenol red-β-D-galactopyranoside (CPRG) 
-   Dissolve 0.01 g CPRG in 1 mL of LGW and store in an amber vial at 4°C 
 
 
Growth media for yeast culture 
-   Prepare growth media fresh just before use  
 
-   Add 23.8 mL assay medium (minimal media + L-aspartic acid + L-threonine), 2.5 mL of the 
20% D (+)-glucose solution, 0.25 mL of the vitamin solution and 63 µL of the 20mM CuSO4  










Ura-Trp Solid media for yeast cell propagation (500 mL): 
-   3.35 g Yeast Nitrogen Base without amino acids and ammonium sulfate 
-   2.5 g ammonium sulfate 
-   2.5 mL of 4 mg/mL adenine sulfate solution 
-   10 g anhydrous dextrose 
-   2.5 g casamino acids 
-   Dissolve in 500 mL LGW  
-   Filter sterilize using a disposable filter/storage sterilization system  
 
-   Add 10 g of bacto agar to 500 mL liquid Ura-Trp media in sterile storage vessel 
 
-   Shake well and transfer to a 1L Erlenmeyer flask  
 
-   Autoclave using the liquid cycle and limit sterilization time to 15 minutes because a longer 
one will degrade dextrose in the media 
 
-   Place autoclaved container under hood and allow to cool until it can be handled without 
difficulty. Do not shake the contents of the autoclaved bottle at this point because this would 
cause bubbles to be present in the media 
 
-   Pour 20-25 mL of media into disposable sterile petri dishes 
-   Let stand at room temperature to harden 
-   Place petri plates in dated ziploc bags and store at 4°C. 
 
17-β-estradiol (E2) solutions (in 100% ethanol): 
-   1E-2M E2 stock: dissolve 27.38 mg E2 in a 10 mL volumetric flask with ethanol 
-   1E-4M E2: add 100 µL of 1E-2M E2 stock solution to a 10 mL volumetric flask with ethanol 
 
-   1E-6M E2: add 100 µL of 1E-4M E2 solution to a 10 mL volumetric flask with ethanol 
 







5E-8M E2 working solution (in 10% ethanol): 
-   Add 9 mL LGW to an amber vial 
-   Add 0.5 mL ethanol and 0.5 mL 1E-6M E2 solution to the vial 
-   Mix well. Store at 4°C 
-   Make working solution fresh on day of assay for best results 
 
10% Ethanol solution: 
-   Add 9mL LGW to a 50mL falcon tube 
-   Add 1mL ethanol 
-   Vortex to mix 
-   Prepare 10mL of 10% ethanol solution per 96-deep well plate being tested 
 
Part 4: Yeast Cell Propagation and Assay Procedure: 
1.   Yeast cell propagation 
I.   Cell growth on Ura-Trp plates:  A petri dish containing viable yeast colonies was 
provided by North Carolina State University and this dish was subsequently used for 
streaking the next yeast generations.  
 
1)   Using a sterile wand (i.e. metal wand dipped in ethanol and sterilized by a flame), streak 
a single colony of yeast from a previous plate onto an Ura-Trp solid media plate. Seal the 
plate with parafilm and incubate at 30°C. After 60 - 72 hours (when individual colonies 
have reached 1-2 mm in diameter), the plates should be removed from the incubator and 
stored at 4°C.  
NOTE: Plates containing yeast colonies can be stored at 4°C for 2 months; however, it is a good 
practice to streak fresh plates at least every month in order to maintain the yeast colonies.  
 
2. Assay Procedure 
 
DAY 1 
II.        Grow yeast cells in growth media: 






2)   Using a sterile wand, pick up one independent colony from a solid agar plate and               
transfer it to the liquid media in the falcon tube. 
 




III.        Determination of yeast cell density and its dilution using growth media: 
1)   Vortex the falcon tube containing the 48 hour yeast suspension culture by using a       
vortex mixer. Ensure that the 96 well plate reader is turned on at least 10 minutes        
prior to use. 
 
2)   Plate 100 µL (in triplicate) of the yeast suspension on 96-well flat bottom microplate. 
Plate 100 µL (in triplicate) of the growth media on the same plate.  Read the plate at   
an absorbance of 620 nm in a plate reader. 
 
3)   Calculate the total volume of yeast cell solution that is used for each set of                  
 experiments: 
 
a)   Subtract Abs620growth media from Abs620Yeast 
 
b)   Solve for x:  (Abs620Yeast – Abs620growth media)(x µL) = (0.15)(100 µL) 
 
4)   Solve for y:  (x µL)/(100µL) = (y mL)/25 mL) 
 
5)   y mL of yeast + (25-y) mL of growth media = dilution of the yeast suspension needed 
for the assay. 
 
6)   Prepare the yeast dilution calculated in 5). In order to ensure that there is enough         
yeast solution, make 25 mL of diluted yeast suspension per plate being tested.  
 
7)   Check the yeast dilution to make sure that the Abs620 falls in the range of 0.15 and  
0.20 (Once again, subtract Abs620growth media to account for background). 
 
8)   Add 10 µL of CPRG solution per 1 mL of diluted yeast solution and vortex to mix. 
 
IV.       Prepare assay plates:  
 
1)   Using a multichannel pipettor, add 100 µL of 10% ethanol to each of the wells in       
 columns 12-2 of a 96 well flat bottom plate. 
 





A and B (Wells A1 and B1) as shown in Figure A.1. Add 200 µL of sample prepared 
in 10% ethanol, in duplicate, to the first wells in rows C-H. 
 
3)   Using a multichannel pipettor, dilute each column serially in 1:2 dilutions. (Transfer  
100 µL of sample from column 1 to column 2; mix thoroughly by aspirating, then       
transfer 100 µL from column 2 to column 3). Continue the serial dilution across entire 
plate until column 11. After mixing the contents of column 11, withdraw 100  µL and 
discard as waste so that the column 12 wells contain only 10% ethanol, yeast and      
CPRG to act as the negative control for the assay, as shown in Figure A.1. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 





C Sample 1 in rows C and D 
D 
E Sample 2 in rows E and F 
F 
G Sample 3 in rows G and H 
H 
     Figure A.1 YES Assay Template 
V.   Exposure of yeast cell to samples: 
1)   Add 200 µL of the yeast/CPRG solution to each well of the 96 deep well plate 
containing the samples, E2 and negative control, starting in column 12, which 
contains the negative control, and ending in column 1 to avoid cross contamination of 
wells . Ensure that each pipette has the same level of diluted yeast solution and no 
bubbles prior to placing in wells. 
 
2)   Cover plate with a plate sealing film and incubate at 30°C while shaking at ~200 rpm 
for 3 minutes. Remove the plate from the shaker and leave in the incubator for 48 





VI.   Measurement of optical densities (Endpoint): 
  
1)   Measure the absorbance of the plate at 540 and 620 nm. Calculate the corrected               
absorbance as the difference between the chemical absorbance at 540 nm and the       
value obtained when the blank absorbance at 620 nm is subtracted from the chemical        
absorbance at 620 nm. Dose-response curves are obtained by plotting the corrected    
absorbance against the sample concentrations. 
 
2)   Compare the sample’s absorbance at 620 nm to that of the negative control’s average. 





indication of cytotoxicity to the yeast cells due to the presence of the sample. Such     
cytotoxic concentrations are excluded from the data set used to plot the dose response 






APPENDIX B: MATERIALS FOR SOLID PHASE EXTRACTION PROCEDURE 
 
Part 1: Materials needed 
Supleco Vacuum Port Manifold (Sigma Aldrich; St. Louis, MO) 
Strata-X 20mg/6mL Cartridges (Phenomenex; Torrance, CA) 
Strata SAX 500mg/3mL Strong Anion Exchange Cartridges (Phenomenex; Torrance, CA) 
Strata Si1 Silica Cartridges  300mg/3mL (Phenomenex; Torrance, CA) 
Whatman GF/D 2.7µm glass fibre filters (Fisher Scientific; Suwanee, Georgia)  
Whatman 934-AH 1.5µm glass fibre filters (Fisher Scientific; Suwanee, Georgia) 
Sartorius Nylon 0.45µm nylon filter (Fisher Scientific; Suwanee, Georgia) 
 
Part 2: Chemicals Needed 
Chemical CAS # Brand/Source used by Weinberg lab 
 




Honeywell Burdick & Jackson; Muskegon, MI 
 
Methyl-tert-butyl Ether (³99%) 1634-04-4 Sigma Aldrich; St. Louis, MO 
 
Ammonium Hydroxide (ACS) 1336-21-6 Fisher Chemicals; Geel, Belgium 
 
Citric Acid Monohydrate 5949-29-1 Sigma Aldrich; St. Louis, MO 
 
Atenolol 190017 MP Biomedicals; Santa Ana, CA 
 
Ethanol (Molecular Biology 
Grade) 





























Figure C.1. Example YES assay dose response curve for serial dilutions of carbamazepine 
























Figure C.2. Example YES assay dose response curve for serial dilutions of triclosan (1.33E-05M 










































































Figure C.5. Example dose response curve for the source wastewater (unspiked extract) used in 





















Figure C.6. Example dose response curve for the wastewater spiked with the 7 target compounds 



























Figure C.7. Example dose response curve for the extract treated only by the first aerobic column 
























Figure C.8. Example dose response curve for the extract treated by the first aerobic and second 


























Figure C.9. Example dose response curve for the extract treated by all three columns (T8C3) in 























Figure C.10. Example dose response curve for the source wastewater (T0 unspiked) used in the 8 
























Figure C.11. Example dose response curve for the wastewater spiked with the 7 target 

























Figure C.12. Example dose response curve for the extract treated by all three columns (T3C3) in 






















Figure C.13. Example dose response curve for the extract treated by the first aerobic column 























Figure C.14. Example dose response curve for the extract treated by the first aerobic and second 






















Figure C.15. Example dose response curve extract treated by all three columns (T8C3) in the 8 






















Figure C.16. Example dose response curve for source wastewater (T0 unspiked) used in the 12 
























Figure C.17. Example dose response curve for the extract treated only by the first aerobic 
























Figure C.18. Example dose response curve for extract treated by the first aerobic and second 

























Figure C.19. Example dose response curve for extract treated by all three columns (T7C3) in the 
























Figure C.20 Example dose response curve for the source wastewater (Unspiked Extract) used in 


























Figure C.21. Example dose response curve for the wastewater spiked with the 7 target 






















Figure C.22. Example dose response curve for extract treated by all three columns (T5C3) in the 


























Figure C.23. Example dose response curve for the extract treated by the first aerobic column 
























Figure C.24. Example dose response curve for the extract treated by the first aerobic and second 


























Figure C.25. Example dose response curve for extract treated by all three columns (T9C3) for the 
























Figure C.26. Example dose response curve for the wastewater spiked with the 7 target 

























Figure C.27. Example dose response curve for the extract treated by the first aerobic column 
























Figure C.28. Example dose response curve for the extract treated by the first aerobic and second 
























Figure C.29. Example dose response curve for extract treated by all three columns (T4C3) in the 









APPENDIX D: SUPPLEMENTAL TABLES  
 
 
Chemical concentrations presented in this appendix comes from LCMS analysis 
conducted by and described in detail by Holmes (2017). Chemical concentrations are given as 
the concentration of the analyte in the extract and not the source wastewater, and have all been 
adjusted to account for the different recoveries listed in Table D.1.  The limit of detection for this 
method is 5 µg/L. Non detect indicates no peak was observed on the LCMS for that chemical.  
 
 
Table D.1. Batch Study Replicate Percent Removals 



















1 Hour 47.9 43.0 26.6 20.5 37.1 37.8 
8 Hours 43.7 34.6 14.1 38.2 50.0 40.2 
24 Hours 70.1 64.0 67.4 68.1 75.3 75.9 
 
 
Table D.2. Calculated SPE Method Recovery for each Target Analyte  
 ATZ CAF CBZ DEET E2 NP 




Table D.3. Estrogenic Analyte Concentrations Detected by LCMS for Batch Study SPE Extracts 
Sample ATZ E2  4-NP  
T0 Unspiked <5 µg/L  <5 µg/L 4.81 mg/L 
T0 + 100 µg/Lb 6.63 mg/L 1.25 mg/L 10.1 mg/L 
1hr Aerobic 344 µg/L 2.43 mg/L 6.27mg/L 
8hr Aerobic 399 µg/L 1.42 mg/L 8.43 mg/L 
24hr Aerobic 303 µg/L <5 µg/L 7.10 mg/L 
1hr Hypoxic 364 µg/L 89.5 µg/L 6.30 mg/L 
8hr Hypoxic 356 µg/L <5 µg/L 5.40 mg/L 










Table D.4. Estrogenic Analyte Concentrations Detected by LCMS for 8hr Study SPE Extracts 
Sample ATZ E2 4-NP 
T0 Unspiked <5 µg/L Non Detect  <5 µg/L 
T0 + 100 µg/L 6.63 mg/L 1.25 mg/L 10.1 mg/L 
T3C3 5.78 mg/L Non Detect 6.83 mg/L 
T8C1 6.06 mg/L 2.17 mg/L <5 µg/L 
T8C2 5.11 mg/L Non Detect <5 µg/L 
T8C3 5.16 mg/L Non Detect <5 µg/L 
 
 
Table D.5. Estrogenic Analyte Concentrations Detected by LCMS for 8hr Flooding SPE Extracts 
Sample ATZ E2 4-NP 
T0 Unspiked 61.2 µg/L Non Detect 434 µg/L 
T0 + 100 µg/L 6.63 mg/L 1.25 mg/L 10.1 mg/L 
T3C3 5.44 mg/L Non Detect 196 µg/L 
T8C1 6.60 mg/L 1.31 mg/L 690 µg/L 
T8C2 7.12 mg/L Non Detect 561 µg/L 
T8C3 6.13 mg/L Non Detect 81.7 µg/L 
 
 
Table D.6. 12 Hour Column 3 Extract Replicate Removals 
 Replicate Removal (%) Replicate Removal (%) Replicate Removal (%) 
T3C3 99.9 99.9 99.9 




Table D.7. Estrogenic Analyte Concentrations Detected by LCMS for 12hr Study SPE Extracts 
Sample ATZ E2 4-NP 
T0 Unspiked <5 µg/L Non Detect 88.5 µg/L 
T0 + 100 µg/L 6.63 mg/L 1.25 mg/L 10.1 mg/L 
T3C3 6.98 mg/L Non Detect <5 µg/L 
T7C1 8.67 mg/L 319 µg/L 1.06 mg/L 
T7C2 6.12 mg/L Non Detect <5 µg/L 









Table D.8. Estrogenic Analyte Concentrations Detected by LCMS for 24hr Study SPE Extracts 
Sample ATZ E2 4-NP 
T0 Unspiked <5 µg/L Non Detect 240 µg/L 
T0 + 100 µg/L 6.63 mg/L 1.25 mg/L 10.1 mg/L 
T5C3 4.05 mg/L 10.3 µg/L 265 µg/L 
T9C1 7.87 mg/L 428 µg/L 2.02 mg/L 
T9C2 7.61 mg/L 68.8 µg/L 593 µg/L 




Table D.9. Estrogenic Analyte Concentrations Detected by LCMS for 36hr Study SPE Extracts 
Sample  ATZ E2 4-NP 
T0 Unspiked 115 µg/L Non Detect <5 µg/L 
T0 + 100 µg/L 6.63 mg/L 1.25 mg/L 10.1 mg/L 
T4C1 6.59 mg/L 679 µg/L 383 µg/L 
T4C2 3.24 mg/L Non Detect <5 µg/L 
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